

**Department of Oncology Annual Report 2015**  
**Publications**

**Sharon Abish**

1. Skamene S, **Abish S**, Mitchell D, Freeman C. Radiotherapy is Important for Local Control at Primary and Metastatic Sites in Pediatric Rhabdomyosarcoma. *Cureus*. 2015 Nov 23;7(11):e388. doi: 10.7759/cureus.388.
2. Shilo NR, Alawadi A, Allard-Coutu A, Robitaille N, Pastore Y, Bérubé D, Jacob SV, **Abish S**, Dauletbaev N, Lands LC. Airway hyperreactivity is frequent in non-asthmatic children with sickle cell disease. *Pediatr Pulmonol*. 2015 Dec 30. doi: 10.1002/ppul.23374. [Epub ahead of print]

**Bassam Abdulkarim**

1. Ayman Oweida, Zeinab Sharifi, Xu Yaoxian, Siham Sabri\*, **Bassam Abdulkarim\***. Differential Response to Ablative Ionizing Radiation in Genetically Distinct Non-Small Cell Lung Cancer Cells.
2. Karen Jung, Ying Wayne Wang, Yaoxian Xu, John Hanson, Siham Sabri, **Bassam Abdulkarim**. Elevated ARG1 expression in primary monocytes-derived macrophages is an independent predictive biomarker of acute radiation-induced skin toxicities in breast cancer patients. *Cancer Biol Ther*. 2015, 16(9):1281-8 [Epub ahead of print].
3. Karen Jung, Nidhi Gupta, Peng Wang, Jamie Lewis, Keshav Gopal, Fang Wu, Xiaoxia Ye, Abdulraheem Alshareef, **Bassam Abdulkarim**, and Raymond Lai. Triple negative breast cancers comprise a highly tumorigenic cell subpopulation detectable by its high responsiveness to a Sox2 regulatory region 2 (SRR2) reporter" by. *Oncotarget*. 2015 Apr 30;6(12):10366-73
4. Melissa Azoulay, Fabiano Santos, Luis Souhami, Valerie Panet-Raymond, Kevin Petrecca, Scott Owen, Marie-Christine Guiot, Maria Patyka, Siham Sabri, George Shenouda, **Bassam Abdulkarim**. Comparison of radiation regimens in the treatment of Glioblastoma multiforme: Results from a Single Institution. *Radiation Oncology* 2015 Apr 26; 10 (1):106. PMID: 25927334.
5. Whelan TJ, Olivotto IA, Parulekar WR, Ackerman I, Chua BH, Nabid A, Vallis KA, White JR, Rousseau P, Fortin A, Pierce LJ, Manchul L, Chafe S, Nolan MC, Craighead P, Bowen J, McCready DR, Pritchard KI, Gelmon K, Murray Y, Chapman JA, Chen BE, Levine MN; **MA.20 Study Investigators**. Regional Nodal Irradiation in Early-Stage Breast Cancer. *N Engl J Med*. 2015 Jul 23;373(4):307-16. doi: 10.1056/NEJMoa1415340.

**Jason Agulnik**

1. Hoffer LJ, Robitaille L, Zakarian R, Melnychuk D, Kavan P, **Agulnik J**, Cohen V, Small D, Miller WH Jr.. High-dose intravenous vitamin C combined with cytotoxic chemotherapy in patients with advanced cancer: a phase I-II clinical trial. *PLoS One*. 2015 Apr 7;10(4):e0120228. doi: 10.1371/journal.pone.0120228. eCollection 2015.

**Hani Al-Halabi**

1. **Al-Halabi H**, Sayegh K, Digamurthy S, Niemierko A, Willers H, Sequist LV. Patterns of Failure in EGFR-Mutant Lung Adenocarcinoma Following Tyrosine Kinase Inhibitor

Therapy: Candidates for Stereotactic Body Radiation Therapy. *J Thorac Oncol*. 2015 Nov;10(11):1601-7.

2. **Al-Halabi H**, Paetzold P, Olsen C, Bortfeld T, Willers H. A Contralateral Esophagus Sparing Technique To Limit Severe Esophagitis Associated With Concurrent High-Dose Radiation And Chemotherapy In Patients With Thoracic Malignancies. *Int J Radiat Oncol Biol Phys*. 2015 Jul; 92( 4):803–810

### **Moulay Alaoui-Jamali**

1. da Silva SD, Marchi FA, Xu B, Bijian K, Alobaid F, Mlynarek A, Rogatto SR, Hier M, Kowalski LP, **Alaoui-Jamali MA**. Predominant Rab-GTPase amplicons contributing to oral squamous cell carcinoma progression to metastasis. *Oncotarget*. 2015 Sep 8;6(26):21950-63.
2. **Alaoui-Jamali M**. Comment on "p38 MAPK inhibition alleviates experimental acute pancreatitis in mice". *Hepatobiliary Pancreat Dis Int*. 2015 Jun;14(3):330.
3. **Alaoui-Jamali MA**, Morand GB, da Silva SD. ErbB polymorphisms: insights and implications for response to targeted cancer therapeutics. *Front Genet*. 2015 Feb 4;6:17. doi: 10.3389/fgene.2015.00017
4. Peña-Hernández R, Marques M, Hilmi K, Zhao T, Saad A, **Alaoui-Jamali MA**, del Rincon SV, Ashworth T, Roy AL, Emerson BM, Witcher M. Genome-wide targeting of the epigenetic regulatory protein CTCF to gene promoters by the transcription factor TFII-I. *Proc Natl Acad Sci U S A*. 2015 Feb 17;112(7):E677-86. doi: 10.1073/pnas.1416674112. Epub 2015 Feb 2.
5. da Silva SD, Morand GB, Alobaid FA, Hier MP, Mlynarek AM, **Alaoui-Jamali MA**, Kowalski LP. Epithelial-mesenchymal transition (EMT) markers have prognostic impact in multiple primary oral squamous cell carcinoma. *Clin Exp Metastasis*. 2015 Jan;32(1):55-63. doi: 10.1007/s10585-014-9690-1. Epub 2014 Nov 30.

### **Thierry Alcindor**

1. Chu QS, Nielsen TO, **Alcindor T**, Gupta A, Endo M, Goytain A, Xu H, Verma S, Tozer R, Knowing M, Bramwell VB, Powers J, Seymour LK, Eisenhauer EA. A Phase II study of SB939, a novel pan-histone deacetylase inhibitor, in patients with translocation-associated recurrent/metastatic sarcomas- NCIC-CTG IND 200. *Annals of Oncology*. 2015 Jan 28. pii: mdv033. [Epub ahead of print]

### **Raquel Aloyz**

1. Abu-Sanad A, Wang Y, Hasheminasab F, Panasci J, Noë A, Rosca L, Davidson D, Amrein L, Sharif-Askari B, **Aloyz R**, Panasci L. Simultaneous inhibition of ATR and PARP sensitizes colon cancer cell lines to irinotecan. *Front Pharmacol*. 2015 Jul 22;6:147. doi: 10.3389/fphar.2015.00147.
2. Eric R. Paquet, Jing Cui, David Davidson, Natalia Pietrosemoli, Houssein Hajj Hassan, Serges P. Tsofack, Annie Maltais, Michael T. Hallett, Mauro Delorenzi, Gerald Batist, Raquel Aloyz and Michel Lebel A 12-gene signature to distinguish colon cancer patients with better clinical outcome following treatment with 5-fluorouracil or FOLFIRI. *The Journal of Pathology: Clinical Research*, Volume 1, Issue 3, July 2015, Pages: 160–172

### Armen Aprikian

1. Chevalier S, Moffett S, Turcotte E, Luz M, Chauvette L, Derbekyan V, Scarlata E, Zouanat F, **Aprikian AG**, Anidjar M. The dog prostate cancer (DPC-1) model: a reliable tool for molecular imaging of prostate tumors and metastases. *EJNMMI Res.* 2015 Dec;5(1):77. doi: 10.1186/s13550-015-0155-6. Epub 2015 Dec 30.
2. Kassouf W, Traboulsi SL, Kulkarni GS, Breau RH, Zlotta A, Fairey A, So A, Lacombe L, Rendon R, **Aprikian AG**, Siemens DR, Izawa JI, Black P. CUA guidelines on the management of non-muscle invasive bladder cancer.
3. *Can Urol Assoc J.* 2015 Sep-Oct;9(9-10):E690-704. doi: 10.5489/cuaj.3320. Epub 2015 Oct 13.
4. Florianova L, Xu B, Traboulsi S, Elmansi H, Tanguay S, Aprikian A, Kassouf W, Brimo F. Evaluation of RNA-binding motif protein 3 expression in urothelial carcinoma of the bladder: an immunohistochemical study. *World J Surg Oncol.* 2015 Nov 14;13:317. doi: 10.1186/s12957-015-0730-3.
5. Blanc-Lapierre A, Spence A, Karakiewicz PI, **Aprikian A**, Saad F, Parent MÉ. Metabolic syndrome and prostate cancer risk in a population-based case-control study in Montreal, Canada. *BMC Public Health.* 2015 Sep 18;15(1):913. doi: 10.1186/s12889-015-2260-x.
6. Brimo F, Dauphin-Pierre S, **Aprikian A**, Kassouf W, Tanguay S, Ajise O, Dongo C, Bégin LR. Inverted urothelial carcinoma: a series of 12 cases with a wide morphologic spectrum overlapping with the large nested variant. *Hum Pathol.* 2015 Oct;46(10):1506-13. doi: 10.1016/j.humpath.2015.06.010. Epub 2015 Jun 26.
7. Santos F, Dragomir A, Zakaria AS, Kassouf W, **Aprikian A**. Health-care services utilization and costs associated with radical cystectomy for bladder cancer: a descriptive population-based study in the province of Quebec, Canada. *BMC Health Serv Res.* 2015 Aug 5;15:308. doi: 10.1186/s12913-015-0972-3.
8. Klil-Drori AJ, Yin H, Tagalakis V, Aprikian A, Azoulay L. Androgen Deprivation Therapy for Prostate Cancer and the Risk of Venous Thromboembolism. *Eur Urol.* 2015 Jun 29. pii: S0302-2838(15)00525-4. doi: 10.1016/j.eururo.2015.06.022. [Epub ahead of print]
9. Al-Qaoud T, Brimo F, **Aprikian AG**, Andonian S. BCG-related renal granulomas managed conservatively: A case series. *Can Urol Assoc J.* 2015 Mar-Apr;9(3-4):E200-3. doi: 10.5489/cuaj.2664.
10. Zakaria AS, Santos F, Tanguay S, Kassouf W, Aprikian AG. Radical cystectomy in patients over 80 years old in Quebec: A population-based study of outcomes. *J Surg Oncol.* 2015 Jun;111(7):917-22. doi: 10.1002/jso.23887. Epub 2015 Feb 8.

### Sarit Assouline

1. Morin RD, **Assouline S**, Alcaide M, Mohajeri A, Johnston RL, Chong L, Grewal J, Yu S, Fornika D, Bushell K, Nielsen TH, Petrogiannis-Halioitis T, Crump M, Tosikyan A, Grande BM, MacDonald D, Rousseau C, Bayat M, Sesques P, Froment R, Albuquerque M, Monczak Y, Oros KK, Greenwood C, Riazalhosseini Y, Arseneault M, Camlioglu E, Constantin A, Pan-Hammarstrom Q, Peng R, Mann KK, Johnson NA. Genetic Landscapes of Relapsed and Refractory Diffuse Large B-Cell Lymphomas. *Clin Cancer Res.* 2015 Dec 8. [Epub ahead of print]
2. Owen C, **Assouline S**, Kuruvilla J, Uchida C, Bellingham C, Sehn L. Novel Therapies for Chronic Lymphocytic Leukemia: A Canadian Perspective. *Clin Lymphoma Myeloma Leuk.* 2015 Nov;15(11):627-634.e5. doi: 10.1016/j.clml.2015.07.649. Epub 2015 Aug 5.

3. Mori S, Vagge E, le Coutre P, Abruzzese E, Martino B, Pungolino E, Elena C, Pierri I, **Assouline S**, D'Emilio A, Gozzini A, Giraldo P, Stagno F, Iurlo A, Luciani M, De Riso G, Redaelli S, Kim DW, Pirola A, Mezzatesta C, Petroccione A, Lodolo D'Oria A, Crivori P, Piazza R, Gambacorti-Passerini C. Age and dPCR can predict relapse in CML patients who discontinued imatinib: the ISAV study. *Am J Hematol*. 2015 Oct;90(10):910-4. doi: 10.1002/ajh.24120. Epub 2015 Sep 10.
4. Marton A, Kezouh A, Petrogiannis-Haliotis T, **Assouline S**. Barriers to enrollment of patients with recurrent diffuse large B-cell lymphoma onto clinical trials. *Leuk Lymphoma*. 2015;56(9):2747-9. doi: 10.3109/10428194.2015.1010079. Epub 2015 Feb 17.

### **Laurent Azoulay**

1. Tuccori M\*, Wu JW, Yin H, Majdan A, **Azoulay L**. The use of glyburide compared with other sulfonylureas and the risk of cancer in patients with type 2 diabetes. *Diabetes Care* 2015;38(11):2083-2089.
2. **Azoulay L**, Eberg M, Benayoun S, Pollak MN. 5-alpha reductase inhibitors and the risk of cancer-related mortality in men with prostate cancer. *JAMA Oncol* 2015;1(3):314-320.
3. Klil-Drori A\*, Yin H, Tagalakis V, Aprikian A, **Azoulay L**. Androgen deprivation therapy for prostate cancer and the risk of venous thromboembolism. *Eur Urol* 2015(epub ahead of print).
4. Breugom AJ, Vermeer TA, van den Broek CBM, Vuong T, Bastiaannet E, **Azoulay L**, Dekkers OM, Niazi T, van den Berg HA, Rutten HJT, van de Velde CJH. Effect of preoperative treatment strategies on the outcome of patients with clinical T3, non-metastasized rectal cancer: a comparison between Dutch and Canadian expert centers. *Eur J Surg Oncol* 2015;41(8):1039-44.
5. **Azoulay L**. Incretin-based drugs and adverse pancreatic events: almost a decade later and uncertainty remains. *Diabetes Care* 2015 38(6):951-3. [Invited Editorial]
6. Yu OH, Yin H, **Azoulay L**. The combination of DPP-4 inhibitors versus sulfonylureas with metformin after failure of first line treatment in the risk for major cardiovascular events and death. *Can J Diabetes* 2015;39(5):383-389.
7. Faillie JL\*, Filion KB, Patenaude V, Ernst P, **Azoulay L**. DPP-4 inhibitors and the risk of community-acquired pneumonia in patients with type 2 diabetes. *Diabetes Obes Metab* 2015;17(4):379-85.
8. Fournier JP\*, **Azoulay L**, Yin H, Montastruc JL, Suissa S. Tramadol use and the risk of hospitalization for hypoglycemia in patients with noncancer pain. *JAMA Intern Med* 2015;175(2):186-93.
9. Assayag J\*, Pollak MN, **Azoulay L**. The use of aspirin and the risk of mortality in patients with prostate cancer. *J Urol* 2015;193(4):1220-5.
10. Fournier JP\*, Yin H, Nessim S, Montastruc JL, **Azoulay L**. Tramadol for non-cancer pain and the risk of hyponatremia. *Am J Med* 2015;128(4):418-25.e5.
11. Lapi F\*, **Azoulay L**, Kezouh A, Benisty IJ, Matok I, Mugelli A, Suissa S. The use of antidepressants and the risk of chronic atrial fibrillation. *J. Clin Pharmacol* 2015;55(4):423-30.
12. Yu OH, Filion KB, **Azoulay L**, Patenaude V, Majdan A, Suissa S. Incretin-based drugs and the risk of congestive heart failure. *Diabetes Care* 2015;38(2):277-84.

### **Boris Bahoric**

1. Rabinovich A, Bernard L, Niazi T, Ramanakumar AV, Gotlieb WH, Lau S, **Bahoric B**. Para-aortic and Pelvic Radiotherapy, an Effective and Safe Treatment in Advanced-stage Uterine Cancer. *Anticancer Research*. Vol. 35(5): 2893-2900.

### **Mark Basik**

1. Dupuy F, Tabariès S, Andrzejewski S, Dong Z, Blagih J, Annis MG, Omeroglu A, Gao D, Leung S, Amir E, Clemons M, Aguilar-Mahecha A, **Basik M**, Vincent EE, St-Pierre J, Jones RG, Siegel PM. PDK1-Dependent Metabolic Reprogramming Dictates Metastatic Potential in Breast Cancer. *Cell Metab*. 2015 Oct 6;22(4):577-89. doi: 10.1016/j.cmet.2015.08.007. Epub 2015 Sep
2. Légaré S, Cavallone L, Mamo A, Chabot C, Sirois I, Magliocco A, Klimowicz A, Tonin PN, Buchanan M, Keilty D, Hassan S, Laperrière D, Mader S, Aleynikova O, **Basik M**. The Estrogen Receptor Cofactor SPEN Functions as a Tumor Suppressor and Candidate Biomarker of Drug Responsiveness in Hormone-Dependent Breast Cancers. *Cancer Res*. 2015 Oct 15;75(20):4351-63. doi: 10.1158/0008-5472.CAN-14-3475. Epub 2015 Aug 21.
3. Hosein AN, Livingstone J, Buchanan M, Reid JF, Hallett M, **Basik M**. A functional in vitro model of heterotypic interactions reveals a role for interferon-positive carcinoma associated fibroblasts in breast cancer. *BMC Cancer*. 2015 Mar 15;15:130. doi:10.1186/s12885-015-1117-0.
4. Boileau JF, Poirier B, **Basik M**, Holloway CM, Gaboury L, Sideris L, Meterissian S, Arnaout A, Brackstone M, McCready DR, Karp SE, Trop I, Lisbona A, Wright FC, Younan RJ, Provencher L, Patocskai E, Omeroglu A, Robidoux A. Sentinel node biopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: the SN FNAC study. *J Clin Oncol*. 2015 Jan 20;33(3):258-64. doi: 10.1200/JCO.2014.55.7827. Epub 2014 Dec 1.

### **Gerald Batist**

1. Rodon J, Soria JC, Berger R, **Batist G**, Tsimberidou A, Bresson C, Lee JJ, Rubin E, Onn A, Schilsky RL, Miller WH, Eggermont AM, Mendelsohn J, Lazar V, Kurzrock R. Challenges in initiating and conducting personalized cancer therapy trials: perspectives from WINTHER, a Worldwide Innovative Network (WIN) Consortium trial. *Ann Oncol*. 2015 Aug;26(8):1791-8.
2. Lazar V, Rubin E, Depil S, Pawitan Y, Martini JF, Gomez-Navarro J, Yver A, Kan Z, Dry JR, Kehren J, Validire P, Rodon J, Vielh P, Ducreux M, Galbraith S, Lehnert M, Onn A, Berger R, Pierotti MA, Porgador A, Pramesh CS, Ye DW, Carvalho AL, **Batist G**, Dann R, Haspel J, Irimie A, Laderman S, Nechushtan H, Al Omari AS, Haywood T, Bresson C, Soo KC, Osman I, Mata H, Lee JJ, Jhaveri K, Meurice G, Palmer G, Lacroix L, Koscielny S, Eterovic KA, Blay JY, Buller R, Eggermont A, Schilsky RL, Mendelsohn J, Soria JC, Rothenberg M, Scoazec JY, Hong WK, Kurzrock R. A simplified interventional mapping system (SIMS) for the selection of combinations of targeted treatments in non-small cell lung cancer. *Oncotarget*. 2015 Jun 10;6(16):14139-52.
3. Stewart DJ, **Batist G**, Kantarjian HM, Bradford JP, Schiller JH, Kurzrock R. The Urgent Need for Clinical Research Reform to Permit Faster, Less Expensive Access to New Therapies for Lethal Diseases. *Clin Cancer Res*. 2015 Oct 15;21(20):4561-8.
4. McLean J, Rho YS, Kuruba G, Mamo A, Gilabert M, Kavan T, Panasci L, Melnychuk D, **Batist G**, Kavan P. Clinical Practice Patterns in Chemotherapeutic Treatment Regimens for

Metastatic Colorectal Cancer. Clin Colorectal Cancer. 2015 Oct 21. pii: S1533-0028(15)00118-8

5. Aboukassim T, Yasmeeen A, Akil N, **Batist G**, Al Moustafa AE. Incidence of Epstein-Barr virus in Syrian women with breast cancer: A tissue microarray study. Hum Vaccin Immunother. 2015;11(4):951-5

### **Nicole Beauchemin**

1. Y.-H. Huang, C. Zhu, Y. Kondo, A. C. Anderson, B.-S. Petersen, E. Melum, H. Iijima, C. Bencsics, K. Sakuishi, M. Raab, **N. Beauchemin**, Q. Chen, R. Grenha, A. Gandhi, J. N. Glickman, C. E. Rudd, A. Franke, V. K. Kuchroo, R. S. Blumberg. CEACAM1 determines TIM-3 mediated tolerance and exhaustion. Nature. 517 (7534) 386-390 (2015). doi: 10.1038/nature13848.
2. Arabzadeh, J. Dupaul-Chicoine, V. Breton, S. Haftchenary, S. Yumeen, C. Turbide, M. Saleh, U.D. Akavia, K. McGregor, C. MT Greenwood, R.S. Blumberg, P.T. Gunning and **N. Beauchemin**. Carcinoembryonic Antigen Cell Adhesion Molecule 1 long isoform modulates malignancy of poorly differentiated colon cancer cells. Gut, February (2015) doi: 10.1136/gutjnl-2014-308781.
3. J. Yip, M.M. Alshahrani, **N. Beauchemin**, and D.E. Jackson. CEACAM1 regulates integrin  $\alpha$ IIb $\beta$ 3-mediated functions in platelets. Platelets, 21, 1-10 (2015).
4. J. Dupaul-Chicoine, A. \*Arabzadeh, M. Dagenais, A. Morizot, I. G. Rodrigue-Gervais, C. Champagne, V. Breton, S. Colpitts, P. Gros, L. Puddington, **N. Beauchemin** and M. Saleh. The Nlrp3 inflammasome suppresses colorectal cancer metastatic growth in the liver by promoting Natural killer cell tumoricidal activity Immunity, 43(4) 751-63 (2015).
5. L. Van Der Kraak, P. Gros and **N. Beauchemin**, Colitis-Associated Colon Cancer: Is it in Your Genes? World Journal of Gastroenterology, 21 (14) 11688-99 2015.
6. CEA Gene Family and Cancer. **N. Beauchemin**. Cancer Encyclopedia 2015.

### **Martin Black**

1. Henry M, Bdira A, Cherba M, Lambert S, Carnevale FA, MacDonald C, Hier M, Zeitouni A, Kost K, Mlynarek A, **Black M**, Rosberger Z, Frenkiel S. Recovering function and surviving treatments are primary motivators for health behavior change in patients with head and neck cancer: Qualitative focus group study. Palliat Support Care. 2015 Nov 23:1-12. [Epub ahead of print]
2. Madana J, Laliberté F, Morand GB, Yolmo D, **Black MJ**, Mlynarek AM, Hier MP. Computerized tomography based tumor-thickness measurement is useful to predict postoperative pathological tumor thickness in oral tongue squamous cell carcinoma. J Otolaryngol Head Neck Surg. 2015 Nov 16;44:49. doi: 10.1186/s40463-015-0089-z.
3. Madana J, Morand GB, Alrasheed A, Gabra N, Laliberté F, Barona-Lleó L, Yolmo D, **Black MJ**, Sultanem K, Hier MP. Clinical parameters predicting development of pulmonary malignancies in patients treated for head and neck squamous cell carcinoma. Head Neck. 2015 Oct 30. doi: 10.1002/hed.24210. [Epub ahead of print]
4. Madana J, Morand GB, Barona-Lleo L, **Black MJ**, Mlynarek AM, Hier MP. A survey on pulmonary screening practices among otolaryngology-head & neck surgeons across Canada in the post treatment surveillance of head and neck squamous cell carcinoma. J Otolaryngol Head Neck Surg. 2015 Feb 4;44:5. doi: 10.1186/s40463-015-0057-7.

### Manuel Borod

1. Fuoco D, di Tomasso J, Boulos C, Kilgour RD, Morais JA, **Borod M**, Vigano A. Identifying nutritional, functional, and quality of life correlates with male hypogonadism in advanced cancer patients. *Ecancermedicalsecience*. 2015 Aug 4;9:561. doi: 10.3332/ecancer.2015.561.

### Nathanial Bouganim

1. Dranitsaris G, Mazzarello S, Smith S, Vandermeer L, **Bouganim N**, Clemons M. Measuring the impact of guideline-based antiemetic therapy on nausea and vomiting control in breast cancer patients with multiple risk factors. *Support Care Cancer*. 2015 Sep 17.
2. Smith AL, Bascuñana C, Hall A, Salman A, Andrei AZ, Volenik A, Rothenmund H, Ferland D, Lamoussenary D, Kamath AS, Amre R, Caglar D, Gao ZH, Haegert DG, Kanber Y, Michel RP, Omeroglu-Altinel G, Asselah J, **Bouganim N**, Kavan P, Arena G, Barkun J, Chaudhury P, Gallinger S, Foulkes WD, Omeroglu A, Metrakos P, Zogopoulos G. Establishing a clinic-based pancreatic cancer and periampullary tumour research registry in Quebec. *Curr Oncol*. 2015 Apr;22(2):113-21. doi: 10.3747/co.22.2300.
3. Mandilaras V, **Bouganim N**, Spayne J, Dent R, Arnaout A, Boileau JF, Brackstone M, Meterissian S, Clemons M. Concurrent chemoradiotherapy for locally advanced breast cancer-time for a new paradigm? *Curr Oncol*. 2015 Feb;22(1):25-32. doi: 10.3747/co.21.2043. Review.

### Philip Branton

1. Mui MZ, Zhou Y, Blanchette P, Chughtai N, Knight JF, Gruosso T, Papadakis AI, Huang S, Park M, Gingras AC, Branton PE. The Human Adenovirus Type 5 E4orf4 Protein Targets Two Phosphatase Regulators of the Hippo Signaling Pathway. *J Virol*. 2015 Sep;89(17):8855-70. doi: 10.1128/JVI.03710-14. Epub 2015 Jun 17.
2. Sriskandarajah N, Blanchette P, Kucharski TJ, Teodoro JG, Branton PE. Analysis by live imaging of effects of the adenovirus E4orf4 protein on passage through mitosis of H1299 tumor cells. *J Virol*. 2015 Apr;89(8):4685-9. doi: 10.1128/JVI.03437-14. Epub 2015 Feb 4.

### Pnina Brodt

1. Ham B, Wang N, D'Costa Z, Fernandez MC, Bourdeau F, Auguste P, Illemann M, Eefsen RL, Høyer-Hansen G, Vainer B, Evrard M, Gao ZH, **Brodt P**. TNF Receptor-2 Facilitates an Immunosuppressive Microenvironment in the Liver to Promote the Colonization and Growth of Hepatic Metastases. *Cancer Res*. 2015 Dec 15;75(24):5235-47. doi: 10.1158/0008-5472.CAN-14-3173. Epub 2015 Oct 19.
2. Li S, Pinard M, Wang Y, Yang L, Lin R, Hiscott J, Su B, **Brodt P**. Crosstalk between the TNF and IGF pathways enhances NF- $\kappa$ B activation and signaling in cancer cells. *Growth Horm IGF Res*. 2015 Oct;25(5):253-61. doi: 10.1016/j.ghir.2015.07.008. Epub 2015 Jul 20.
3. Wang N, Rayes RF, Elahi SM, Lu Y, Hancock MA, Massie B, Rowe GE, Aomari H, Hossain S, Durocher Y, Pinard M, Tabariès S, Siegel PM, **Brodt P**. The IGF-Trap: Novel Inhibitor of Carcinoma Growth and Metastasis. *Mol Cancer Ther*. 2015 Apr;14(4):982-93. doi: 10.1158/1535-7163.MCT-14-0751. Epub 2015 Feb

### Robin Cohen

1. \*Allen D, Badro V, Denyer Willis L, Macdonald ME, Paré A, Hutchinson T, Barré P, Beauchemin R, Bocti H, Broadbent A, **Cohen SR**. Fragmented care and whole-person

- illness: Decision-making for people with chronic, end-stage kidney disease. *Chronic Illness* 2015; 11(1):44-55. doi: 10.1177/1742395314562974
- Lang A, Toon L, **Cohen SR**, Stajduhar K, Griffin M, Easty T, Williams A. Client, caregiver, and provider perspectives of safety issues in palliative home care: A mixed method design. *Safety in Health* 2015; 1:3. doi: 10.1186/2056-5917-1-3
  - \*MacKinnon CJ, Smith NG, Henry M, Milman E, Chochinov HM, Körner A, Berish M, Farrace A, Liarikos N, **Cohen SR**. Reconstructing meaning with others in loss: A feasibility pilot randomized controlled trial of a bereavement group. *Death Studies* 2015; 39: 411-421. doi:10.1080/07481187.2014.958628
  - \*MacKinnon CJ, Smith NG, Henry M, Milman E, Berish M, Farrace A, Körner A, Chochinov HM, **Cohen SR**. A pilot study of meaning-based group counseling for bereavement. *Omega: Journal of Death and Dying* 2016; 72(3): 201-233. doi: 10.1177/0030222815575002
  - Cohen SR** and Sawatzky R. Quality of life assessment in palliative care. In: *Textbook of Palliative Medicine and Supportive Care*, 2nd Edition, E. Bruera, I. Higginson, C.F. von Gunten, and T. Morita eds. CRC Press, London, England. Distributed by Oxford University Press, New York, N.Y.(2015), pp 361-369

#### **Victor Cohen**

- Putt M, Hahn VS, Januzzi JL, Sawaya H, Sebag IA, Plana JC, Picard MH, Carver JR, Halpern EF, Kuter I, Passeri J, **Cohen V**, Banchs J, Martin RP, Gerszten RE, Scherrer-Crosbie M, Ky B. Longitudinal Changes in Multiple Biomarkers Are Associated with Cardiotoxicity in Breast Cancer Patients Treated with Doxorubicin, Taxanes, and Trastuzumab. *Clin Chem*. 2015 Sep;61(9):1164-72. doi: 10.1373/clinchem.2015.241232. Epub 2015 Jul 27.
- Tan TC, Bouras S, Sawaya H, Sebag IA, **Cohen V**, Picard MH, Passeri J, Kuter I, Scherrer-Crosbie M. Time Trends of Left Ventricular Ejection Fraction and Myocardial Deformation Indices in a Cohort of Women with Breast Cancer Treated with Anthracyclines, Taxanes, and Trastuzumab. *J Am Soc Echocardiogr*. 2015 May;28(5):509-14. doi: 10.1016/j.echo.2015.02.001. Epub 2015 Mar 13.

#### **Fabio Cury**

- Smith GD, Pickles T, Crook J, Martin AG, Vigneault E, **Cury FL**, Morris J, Catton C, Lukka H, Warner A, Yang Y, Rodrigues G. Brachytherapy improves biochemical failure-free survival in low- and intermediate-risk prostate cancer compared with conventionally fractionated external beam radiation therapy: a propensity score matched analysis. *Int J Radiat Oncol Biol Phys*. 2015 Mar 1;91(3):505-16.
- Faria S, **Cury F**, Souhami L. Prospective phase I study on testicular castration induced by radiation treatment. *Can J Urol*. 2015 Feb;22(1):7635-9.
- FL Cury**, B Bhindi, J Rocha, E Scarlata, K El Jurdi, M Ladouceur, S Beaugard, AK Vijh, Y Taguchi, S Chevalier. Electrochemical red-ox therapy of prostate cancer in nude mice. *Bioelectrochemistry*. 2015 Aug;104:1-9.
- Coates J, Jeyaseelan AK, Ybarra N, David M, Faria S, Souhami L, **Cury F**, Duclos M, El Naqa I. Contrasting analytical and data-driven frameworks for radiogenomic modeling of normal tissue toxicities in prostate cancer. *Radiother Oncol*. 2015 Apr;115(1):107-13.



5. Lecavalier-Barsoum M, Souhami L, **Cury F**, Duclos M, Ruo R, Faria S. Pelvic lymph node displacement in high-risk prostate cancer patients treated with image guided intensity modulated radiation therapy with 2 independent target volumes. *Pract Radiat Oncol*. 2015 Nov-Dec;5(6):406-10.
6. Shrivastava S, Mansure JJ, Almajed W, **Cury F**, Ferbeyre G, Popovic M, Seuntjens J, Kassouf W. The role of HMGB1 in radio-resistance of bladder cancer. *Mol Cancer Ther*. 2015 Dec 30.

#### **Marc David**

1. Coates J, Jeyaseelan AK, Ybarra N, **David M**, Faria S, Souhami L, Cury F, Duclos M, El Naqa I. Contrasting analytical and data-driven frameworks for radiogenomic modeling of normal tissue toxicities in prostate cancer. *Radiother Oncol*. 2015 Apr;115(1):107-13. doi: 10.1016/j.radonc.2015.03.005. Epub 2015 Mar 25.
2. Sudarshan M, Alcindor T, Ades S, Aloraini A, van Huysse M, Asselah J, **David M**, Frechette D, Brisson S, Thirlwell M, Ferri L. Survival and recurrence patterns after neoadjuvant docetaxel, cisplatin, and 5-fluorouracil (DCF) for locally advanced esophagogastric adenocarcinoma. *Ann Surg Oncol*. 2015 Jan;22(1):324-30. doi: 10.1245/s10434-014-3875-3. Epub 2014 Jul 15.

#### **James Ashley Davidson**

1. Baxter E, Gondara L, Lohrisch C, Chia S, Gelmon K, Hayes M, **Davidson A**, Tyldesley S. Using proliferative markers and Oncotype DX in therapeutic decision-making for breast cancer: the B.C. experience. *Curr Oncol*. 2015 Jun;22(3):192-8.

#### **François DeBlois**

1. S. Asgharizadeh, H. Bekerat, A. Syme, S. Aldelaijan, **F. DeBlois**, T. Vuong, M. Evans, J. Seuntjens, S. Devic, Radiochromic film-based quality assurance for CT-based high-dose-rate brachytherapy, *Brachytherapy*. 2015 Jul-Aug;14(4):578-85 (2015).
2. L Liang, H Bekerat, N Tomic, **F DeBlois**, S Devic, M Morcos, M Popovic, P Watson and J Seuntjens, Impact of the Radiochromic Film Energy Response On Dose Measurements of Low Energy Electronic Brachytherapy Sources, *Med. Phys.* 42, 3440 (2015)

#### **Slobodan Devic**

1. Nobah A, Mohiuddin M, **Devic S**, Moftah B, "Effective Spatially Fractionated GRID Radiation Treatment Planning for a Passive Grid Block," *Br J Radiol* 88, 20140363 (2015); doi: 10.1259/bjr.20140363
2. Bezdjian A, Mujica-Mota MA, **Devic S**, Daniel SJ, "The Effect of Radiotherapy on Gentamicin Ototoxicity: An Animal Model." *Otolaryngol Head Neck Surg*. 2015 Mar 16.
3. Asgharizadeh S, Bekerat H, Syme A, Aldelaijan S, DeBlois F, Vuong T, Evans M, Seuntjens J, **Devic S**, "Radiochromic film-based quality assurance for CT-based high-dose-rate brachytherapy" *Brachytherapy*. 2015 Apr 9. pii: S1538-4721(15)00215-9. doi: 10.1016/j.brachy.2015.02.192
4. Aldosary G, Nobah A, Al-Zorkani F, **Devic S**, Moftah B. "The influence of a modeled treatment couch on dose distributions during IMRT and RapidArc treatment delivery," *Med. Dosim*. 2015 Apr 28. pii: S0958-3947(15)00033-3. doi: 10.1016/j.meddos. 2015.03.008.
5. Lewis D, **Devic S**, "Correcting scan-to-scan response variability for a radiochromic film-

based reference dosimetry system,” *Medical Physics* 42, 5692 (2015); doi: 10.1118/1.4929563

### Marie Duclos

1. Lecavalier-Barsoum M, Souhami L, Cury F, **Duclos M**, Ruo R, Faria S. Pelvic lymph node displacement in high-risk prostate cancer patients treated with image guided intensity modulated radiation therapy with 2 independent target volumes. *Pract Radiat Oncol*. 2015 Nov-Dec;5(6):406-10. doi: 10.1016/j.prro.2015.05.002. Epub 2015 Jun 27.
2. Bruner DW, Hunt D, Michalski JM, Bosch WR, Galvin JM, Amin M, Xiao C, Bahary JP, Patel M, Chafe S, Rodrigues G, Lau H, **Duclos M**, Baikadi M, Deshmukh S, Sandler HM. Preliminary patient-reported outcomes analysis of 3-dimensional radiation therapy versus intensity-modulated radiation therapy on the high-dose arm of the Radiation Therapy Oncology Group (RTOG) 0126 prostate cancer trial. *Cancer*. 2015 Jul 15;121(14):2422-30. doi: 10.1002/cncr.29362. Epub 2015 Apr 2.
3. Coates J, Jeyaseelan AK, Ybarra N, David M, Faria S, Souhami L, Cury F, **Duclos M**, El Naqa I. Contrasting analytical and data-driven frameworks for radiogenomic modeling of normal tissue toxicities in prostate cancer. *Radiother Oncol*. 2015 Apr;115(1):107-13. doi: 10.1016/j.radonc.2015.03.005. Epub 2015 Mar 25.
4. Pisansky TM, Hunt D, Gomella LG, Amin MB, Balogh AG, Chinn DM, Seider MJ, **Duclos M**, Rosenthal SA, Bauman GS, Gore EM, Rotman MZ, Lukka HR, Shipley WU, Dignam JJ, Sandler HM. Duration of androgen suppression before radiotherapy for localized prostate cancer: radiation therapy oncology group randomized clinical trial 9910. *J Clin Oncol*. 2015 Feb 1;33(4):332-9. doi: 10.1200/JCO.2014.58.0662. Epub 2014 Dec 22.

### Nicoletta Eliopoulos

1. Zhao J, Young YK, Fradette J, **Eliopoulos N**. Melatonin pretreatment of human adipose tissue-derived mesenchymal stromal cells enhances their prosurvival and protective effects on human kidney cells. *Am J Physiol Renal Physiol*. 2015 Jun 15;308(12):F1474-83. doi: 10.1152/ajprenal.00512.2014. Epub 2015 Apr 22.

### Shirin Enger

1. Bernal M, Bordage MC, Brown J, Davidkova M, Delage M, El Bitar Z, **SA Enger**, Francis Z, Guatelli S, Ivantchenko V, Karamitros M, Kyriakou I, Maigne L, Meylan S, Murakami K, Okada S, Payno H, Perrot Y, Pham T, Tran H, Sasaki T, Stepan V, Villagrasa C, Incerti S. Track structure modeling in liquid water: a review of the Geant4-DNA very low energy extension of the Geant4 Monte Carlo simulation toolkit. *European Journal of Medical Physics*. 2015; 31:861–874
2. Poole CM, Ahnesjö A, **Enger SA**, Determination of subcellular compartment sizes for estimating dose variations in radiotherapy. *Radiation Protection Dosimetry*. 1-4 (2015).

### Michael Evans

1. R. Maglieri, A. Licea, **M. Evans**, J. Seuntjens, J. Kildea; Measuring neutron spectra in radiotherapy using the nested neutron spectromete.: *Medical Physics*, 42, pp 6162- 6169; November 2015.

2. S. Asgharizadeh, H. Bekerat, A. Syme, S. Aldelaijan, F. DeBlois, T. Vuong, **M. Evans**, J. Seuntjens, S. Devic, ; Radiochromic Film Based Quality Assurance for CT-based High Dose Rate Brachytherapy Brachytherapy, Brachytherapy, 14(4): 578 – 585,

#### **Marc Fabian**

1. Nishimura, T., Padamsi, Z., Fakim, H., Milette, S., Dunham, W., Gingras, A-C., and **Fabian, M.R.** (2015). The eIF4E binding protein 4E-T is a component of the mRNA decay machinery that bridges the 5' and 3' termini of target mRNAs. Cell Reports 11(9):1425-36.

#### **Sergio Faria**

1. Maria OM, Maria AM, Ybarra N, Jeyaseelan K, Lee S, Perez J, Shalaby MY, Lehnert S, **Faria S**, Serban M, Seuntjens J, El Naqa I. Mesenchymal Stem Cells Adopt Lung Cell Phenotype in Normal and Radiation-induced Lung Injury Conditions. Appl Immunohistochem Mol Morphol. 2015 Jul 18. [Epub ahead of print]
2. Lecavalier-Barsoum M, Souhami L, Cury F, Duclos M, Ruo R, **Faria S**. Pelvic lymph node displacement in high-risk prostate cancer patients treated with image guided intensity modulated radiation therapy with 2 independent target volumes. Pract Radiat Oncol. 2015 Nov-Dec;5(6):406-10. doi: 10.1016/j.prro.2015.05.002. Epub 2015 Jun 27.
3. Lee S, Ybarra N, Jeyaseelan K, **Faria S**, Kopek N, Brisebois P, Bradley JD, Robinson C, Seuntjens J, El Naqa I. Bayesian network ensemble as a multivariate strategy to predict radiation pneumonitis risk. Med Phys. 2015 May;42(5):2421-30. doi: 10.1118/1.4915284.
4. Coates J, Jeyaseelan AK, Ybarra N, David M, **Faria S**, Souhami L, Cury F, Duclos M, El Naqa I. Contrasting analytical and data-driven frameworks for radiogenomic modeling of normal tissue toxicities in prostate cancer. Radiother Oncol. 2015 Apr;115(1):107-13. doi: 10.1016/j.radonc.2015.03.005. Epub 2015 Mar 25.
5. **Faria S**, Cury F, Souhami L. Prospective phase I study on testicular castration induced by radiation treatment. Can J Urol. 2015 Feb;22(1):7635-9.

#### **William Foulkes**

1. Schiavi A, Lavigne J, Turcotte R, Kasprzak L, Dumas N, Chong G, Freeman C, Alameldin M, Galiatsatos P, Palma L, **Foulkes WD**. Using a family history questionnaire to identify adult patients with increased genetic risk for sarcoma. Curr Oncol. 2015 Oct;22(5):317-25. doi: 10.3747/co.22.2588.
2. Croce S, de Kock L, Boshari T, Hostein I, Velasco V, **Foulkes WD**, McCluggage WG. Uterine Tumor Resembling Ovarian Sex Cord Tumor (UTROSCT) Commonly Exhibits Positivity With Sex Cord Markers FOXL2 and SF-1 but Lacks FOXL2 and DICER1 Mutations. Int J Gynecol Pathol. 2015 Nov 23. [Epub ahead of print]
3. Rivera B, Castellsagué E, Bah I, van Kempen LC, **Foulkes WD**. Biallelic NTHL1 Mutations in a Woman with Multiple Primary Tumors. N Engl J Med. 2015 Nov 12;373(20):1985-6. doi: 10.1056/NEJMc1506878. Erratum in: N Engl J Med. 2015 Dec 17;373(25):e33.
4. Pelletier S, Wong N, El Haffaf Z, **Foulkes WD**, Chiquette J, Hamet P, Simard J, Dorval M. Clinical follow-up and breast and ovarian cancer screening of true BRCA1/2 noncarriers: a qualitative investigation. Genet Med. 2015 Nov 5. doi: 10.1038/gim.2015.135. [Epub ahead of print]

5. Gavino C, Hamel N, Zeng JB, Legault C, Guiot MC, Chankowsky J, Lejtenyi D, Lemire M, Alarie I, Dufresne S, Boursiquot JN, McIntosh F, Langelier M, Behr MA, Sheppard DC, **Foulkes WD**, Vinh DC. Impaired RASGRF1/ERK-mediated GM-CSF response characterizes CARD9 deficiency in French-Canadians. *J Allergy Clin Immunol*. 2015 Oct 29. pii: S0091-6749(15)01354-8. doi: 10.1016/j.jaci.2015.09.016. [Epub ahead of print]
6. Semple J, Metcalfe KA, Lubinski J, Huzarski T, Gronwald J, Armel S, Lynch HT, Karlan B, **Foulkes W**, Singer CF, Neuhausen SL, Eng C, Iqbal J, Narod SA; Hereditary Breast Cancer Clinical Study Group. Does the age of breast cancer diagnosis in first-degree relatives impact on the risk of breast cancer in BRCA1 and BRCA2 mutation carriers? *Breast Cancer Res Treat*. 2015 Nov;154(1):163-9.
7. Easton DF, Pharoah PD, **Foulkes WD**. ClinGen and Genetic Testing. *N Engl J Med*. 2015 Oct;373(14):1378. doi: 10.1056/NEJMc1508700. No abstract available. PMID: 26422736 Free Article
8. Narod SA, Dent RA, **Foulkes WD**. CCR 20th Anniversary Commentary: Triple-Negative Breast Cancer in 2015—Still in the Ballpark. *Clin Cancer Res*. 2015 Sep 1;21(17):3813-4. doi: 10.1158/1078-0432.CCR-14-3122.
9. Boucherat O, Landry-Truchon K, Bérubé-Simard FA, Houde N, Beuret L, Lezmi G, **Foulkes WD**, Delacourt C, Charron J, Jeannotte L. Epithelial inactivation of Yy1 abrogates lung branching morphogenesis. *Development*. 2015 Sep 1;142(17):2981-95. doi: 10.1242/dev.120469. PMID: 26329601 Free Article
10. Kotsopoulos J, Lubinski J, Neuhausen SL, Gronwald J, Lynch HT, Huzarski T, Demsky R, **Foulkes WD**, Senter L, Friedman S, Ainsworth P, Sun P, Narod SA; Hereditary Breast Cancer Clinical Study Group. Weight gain after oophorectomy among women with a BRCA1 or BRCA2 mutation. *Womens Health (Lond Engl)*. 2015 Jul;11(4):453-9. doi: 10.2217/WHE.15.4. Epub 2015 Aug 10.
11. Antoniou AC, **Foulkes WD**, Tischkowitz M; PALB2 Interest Group. Breast cancer risk in women with PALB2 mutations in different populations. *Lancet Oncol*. 2015 Aug;16(8):e375-6. doi: 10.1016/S1470-2045(15)00002-9.
12. Metcalfe K, Lynch HT, **Foulkes WD**, Tung N, Kim-Sing C, Olopade OI, Eisen A, Rosen B, Snyder C, Gershman S, Sun P, Narod SA. Effect of Oophorectomy on Survival After Breast Cancer in BRCA1 and BRCA2 Mutation Carriers. *JAMA Oncol*. 2015 Jun;1(3):306-13. doi: 10.1001/jamaoncol.2015.0658.
13. Witkowski L, **Foulkes WD**. In Brief: Picturing the complex world of chromatin remodelling families. *J Pathol*. 2015 Dec;237(4):403-6. doi: 10.1002/path.4585. Epub 2015 Aug 19.
14. Rabinovich A, Witkowski L, Shaco-Levi R, Meirovitz M, Hasselblatt M, **Foulkes WD**. Primary rhabdoid tumor of the ovary: When large cells become small cells. *Gynecol Oncol Rep*. 2015 Mar 19;12:64-6. doi: 10.1016/j.gore.2015.03.005. eCollection 2015 Apr.
15. Berchuck A, Witkowski L, Hasselblatt M, **Foulkes WD**. Prophylactic oophorectomy for hereditary small cell carcinoma of the ovary, hypercalcemic type. *Gynecol Oncol Rep*. 2015 Feb 25;12:20-2. doi: 10.1016/j.gore.2015.02.002. eCollection 2015 Apr.
16. Easton DF, Pharoah PD, Antoniou AC, Tischkowitz M, Tavtigian SV, Nathanson KL, Devilee P, Meindl A, Couch FJ, Southey M, Goldgar DE, Evans DG, Chenevix-Trench G, Rahman N, Robson M, Domchek SM, **Foulkes WD**. Gene-panel sequencing and the

- prediction of breast-cancer risk. *N Engl J Med.* 2015 Jun 4;372(23):2243-57. doi: 10.1056/NEJMSr1501341. Epub 2015 May 27. No abstract available.
17. Cybulski C, Lubinski J, Huzarski T, Lynch HT, Randall SA, Neuhausen SL, Senter L, Friedman S, Ainsworth P, Singer C, **Foulkes WD**, Narod SA, Sun P, Kotsopoulos J. Prospective evaluation of alcohol consumption and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. *Breast Cancer Res Treat.* 2015 Jun;151(2):435-41. doi: 10.1007/s10549-015-3393-4. Epub 2015 May 3.
  18. Arcand SL, Akbari MR, Mes-Masson AM, Provencher D, **Foulkes WD**, Narod SA, Tonin PN. Germline TP53 mutational spectrum in French Canadians with breast cancer. *BMC Med Genet.* 2015 Apr 12;16:24. doi: 10.1186/s12881-015-0169-y.
  19. Blein S, Bardel C, Danjean V, McGuffog L, Healey S, Barrowdale D, Lee A, Dennis J, Kuchenbaecker KB, Soucy P, Terry MB, Chung WK, Goldgar DE, Buys SS; Breast Cancer Family Registry, Janavicius R, Tihomirova L, Tung N, Dorfling CM, van Rensburg EJ, Neuhausen SL, Ding YC, Gerdes AM, Ejlersen B, Nielsen FC, Hansen TV, Osorio A, Benitez J, Conejero RA, Segota E, Weitzel JN, Thelander M, Peterlongo P, Radice P, Pensotti V, Dolcetti R, Bonanni B, Peissel B, Zaffaroni D, Scuvera G, Manoukian S, Varesco L, Capone GL, Papi L, Ottini L, Yannoukakos D, Konstantopoulou I, Garber J, Hamann U, Donaldson A, Brady A, Brewer C, Foo C, Evans DG, Frost D, Eccles D; EMBRACE, Douglas F, Cook J, Adlard J, Barwell J, Walker L, Izatt L, Side LE, Kennedy MJ, Tischkowitz M, Rogers MT, Porteous ME, Morrison PJ, Platte R, Eeles R, Davidson R, Hodgson S, Cole T, Godwin AK, Isaacs C, Claes K, De Leeneer K, Meindl A, Gehrig A, Wappenschmidt B, Sutter C, Engel C, Niederacher D, Steinemann D, Plendl H, Kast K, Rhiem K, Ditsch N, Arnold N, Varon-Mateeva R, Schmutzler RK, Preisler-Adams S, Markov NB, Wang-Gohrke S, de Pauw A, Lefol C, Lasset C, Leroux D, Rouleau E, Damiola F; GEMO Study Collaborators, Dreyfus H, Barjhoux L, Golmard L, Uhrhammer N, Bonadona V, Sornin V, Bignon YJ, Carter J, Van Le L, Piedmonte M, DiSilvestro PA, de la Hoya M, Caldes T, Nevanlinna H, Aittomäki K, Jager A, van den Ouweland AM, Kets CM, Aalfs CM, van Leeuwen FE, Hogervorst FB, Meijers-Heijboer HE; HEBON, Oosterwijk JC, van Roozendaal KE, Rookus MA, Devilee P, van der Luijt RB, Olah E, Diez O, Teulé A, Lazaro C, Blanco I, Del Valle J, Jakubowska A, Sukiennicki G, Gronwald J, Lubinski J, Durda K, Jaworska-Bieniek K, Agnarsson BA, Maugard C, Amadori A, Montagna M, Teixeira MR, Spurdle AB, **Foulkes W**, Olszowol C, Lindor NM, Pankratz VS, Szabo CI, Lincoln A, Jacobs L, Corines M, Robson M, Vijai J, Berger A, Fink-Retter A, Singer CF, Rappaport C, Kaulich DG, Pfeiler G, Tea MK, Greene MH, Mai PL, Rennert G, Imyanitov EN, Mulligan AM, Glendon G, Andrulis IL, Tchatchou S, Toland AE, Pedersen IS, Thomassen M, Kruse TA, Jensen UB, Caligo MA, Friedman E, Zidan J, Laitman Y, Lindblom A, Melin B, Arver B, Loman N, Rosenquist R, Olopade OI, Nussbaum RL, Ramus SJ, Nathanson KL, Domchek SM, Rebbeck TR, Arun BK, Mitchell G, Karlan BY, Lester J, Orsulic S, Stoppa-Lyonnet D, Thomas G, Simard J, Couch FJ, Offit K, Easton DF, Chenevix-Trench G, Antoniou AC, Mazoyer S, Phelan CM, Sinilnikova OM, Cox DG. An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers. *Breast Cancer Res.* 2015 Apr 25;17:61. doi: 10.1186/s13058-015-0567-2.

20. Cybulski C, Carrot-Zhang J, Kluźniak W, Rivera B, Kashyap A, Wokołorczyk D, Giroux S, Nadaf J, Hamel N, Zhang S, Huzarski T, Gronwald J, Byrski T, Szwiec M, Jakubowska A, Rudnicka H, Lener M, Masojć B, Tonin PN, Rousseau F, Górski B, Dębniak T, Majewski J, Lubiński J, **Foulkes WD**, Narod SA, Akbari MR. Germline RECQL mutations are associated with breast cancer susceptibility. *Nat Genet.* 2015 Jun;47(6):643-6. doi: 10.1038/ng.3284. Epub 2015 Apr 27.
21. Smith AL, Bascuñana C, Hall A, Salman A, Andrei AZ, Volenik A, Rothenmund H, Ferland D, Lamoussenerly D, Kamath AS, Amre R, Caglar D, Gao ZH, Haegert DG, Kanber Y, Michel RP, Omeroglu-Altinel G, Asselah J, Bouganim N, Kavan P, Arena G, Barkun J, Chaudhury P, Gallinger S, **Foulkes WD**, Omeroglu A, Metrakos P, Zogopoulos G. Establishing a clinic-based pancreatic cancer and periampullary tumour research registry in Quebec. *Curr Oncol.* 2015 Apr;22(2):113-21. doi: 10.3747/co.22.2300.
22. Oost EE, Charles A, Choong CS, Leung YC, Salfinger S, Sonnendecker H, Tan J, Townshend S, Witkowski L, **Foulkes WD**, Stewart CJ. Ovarian sex cord-stromal tumors in patients with probable or confirmed germline DICER1 mutations. *Int J Gynecol Pathol.* 2015 May;34(3):266-74. doi: 10.1097/PGP.0000000000000150.
23. Amin AI, Olama A, Benlloch S, Antoniou AC, Giles GG, Severi G, Neal DE, Hamdy FC, Donovan JL, Muir K, Schleutker J, Henderson BE, Haiman CA, Schumacher FR, Pashayan N, Pharoah PD, Ostrander EA, Stanford JL, Batra J, Clements JA, Chambers SK, Weischer M, Nordestgaard BG, Ingles SA, Sorensen KD, Orntoft TF, Park JY, Cybulski C, Maier C, Doerk T, Dickinson JL, Cannon-Albright L, Brenner H, Rebbeck TR, Zeigler-Johnson C, Habuchi T, Thibodeau SN, Cooney KA, Chappuis PO, Hutter P, Kaneva RP, **Foulkes WD**, Zeegers MP, Lu YJ, Zhang HW, Stephenson R, Cox A, Southey MC, Spurdle AB, FitzGerald L, Leongamornlert D, Saunders E, Tymrakiewicz M, Guy M, Dadaev T, Little SJ, Govindasami K, Sawyer E, Wilkinson R, Herkommer K, Hopper JL, Lophatonanon A, Rinkleb AE, Kote-Jarai Z, Eeles RA, Easton DF; UK Genetic Prostate Cancer Study Collaborators/British Association of Urological Surgeons' Section of Oncology; UK ProtecT Study Collaborators; PRACTICAL Consortium. Risk Analysis of Prostate Cancer in PRACTICAL, a Multinational Consortium, Using 25 Known Prostate Cancer Susceptibility Loci. *Cancer Epidemiol Biomarkers Prev.* 2015 Jul;24(7):1121-9. doi: 10.1158/1055-9965.EPI-14-0317. Epub 2015 Apr 2.
24. de Kock L, Druker H, Weber E, Hamel N, Traubici J, Malkin D, Arseneau J, Stewart CJ, Bouron-Dal Soglio D, Priest JR, **Foulkes WD**. Ovarian embryonal rhabdomyosarcoma is a rare manifestation of the DICER1 syndrome. *Hum Pathol.* 2015 Jun;46(6):917-22. doi: 10.1016/j.humpath.2015.02.008. Epub 2015 Mar 5.
25. Sabapathy DG, Guillerman RP, Orth RC, Zhang W, Messinger Y, **Foulkes W**, Priest JR, Annapragada AV. Radiographic screening of infants and young children with genetic predisposition for rare malignancies: DICER1 mutations and pleuropulmonary blastoma. *AJR Am J Roentgenol.* 2015 Apr;204(4):W475-82. doi: 10.2214/AJR.14.12802.
26. Galiatsatos P, Rothenmund H, Aubin S, **Foulkes WD**. Psychosocial Impact of Lynch Syndrome on Affected Individuals and Families. *Dig Dis Sci.* 2015 Aug;60(8):2246-50. doi: 10.1007/s10620-015-3626-8. Epub 2015 Mar 19. Review.
27. Castellsagué E, **Foulkes WD**. Lynch syndrome: five unanswered questions. *Clin Genet.* 2015

- Jun;87(6):503-6. doi: 10.1111/cge.12580. Review. No abstract available.
28. Li L, Hamel N, Baker K, McGuffin MJ, Couillard M, Gologan A, Marcus VA, Chodirker B, Chudley A, Stefanovici C, Durandy A, Hegele RA, Feng BJ, Goldgar DE, Zhu J, De Rosa M, Gruber SB, Wimmer K, Young B, Chong G, Tischkowitz MD, **Foulkes WD**. A homozygous PMS2 founder mutation with an attenuated constitutional mismatch repair deficiency phenotype. *J Med Genet*. 2015 May;52(5):348-52. doi: 10.1136/jmedgenet-2014-102934. Epub 2015 Feb
29. Bailey S, Murray MJ, Witkowski L, Hook E, Hasselblatt M, Crawford R, **Foulkes WD**, Tischkowitz M, Nicholson JC. Biallelic somatic SMARCA4 mutations in small cell carcinoma of the ovary, hypercalcemic type (SCCOHT). *Pediatr Blood Cancer*. 2015 Apr;62(4):728-30. doi: 10.1002/pbc.25279. Epub 2014 Oct 12.

### **Eduardo Franco**

1. Santesso N, Mustafa RA, Schünemann HJ, Arbyn M, Blumenthal PD, Cain J, Chirenje M, Denny L, De Vuyst H, Eckert LO, Forhan SE, **Franco EL**, Gage JC, Garcia F, Herrero R, Jeronimo J, Lu ER, Luciani S, Quek SC, Sankaranarayanan R, Tsu V, Broutet N; Guideline Support Group. World Health Organization Guidelines for treatment of cervical intraepithelial neoplasia 2-3 and screen-and-treat strategies to prevent cervical cancer. *Int J Gynaecol Obstet*. 2016 Mar;132(3):252-8. doi: 10.1016/j.ijgo.2015.07.038. Epub 2015 Dec 14.
2. El-Zein M, Richardson L, **Franco EL**. Cervical cancer screening of HPV vaccinated populations: Cytology, molecular testing, both or none. *J Clin Virol*. 2016 Mar;76 Suppl 1:S62-8. doi: 10.1016/j.jcv.2015.11.020. Epub 2015 Nov 18.
3. Laprise C, Madathil SA, Allison P, Abraham P, Raghavendran A, Shahul HP, ThekkePurakkal AS, Castonguay G, Coutlée F, Schlecht NF, Rousseau MC, **Franco EL**, Nicolau B. No role for human papillomavirus infection in oral cancers in a region in southern India. *Int J Cancer*. 2016 Feb 15;138(4):912-7. doi:10.1002/ijc.29827. Epub 2015 Sep 14.
4. Cook DA, Mei W, Smith LW, van Niekerk DJ, Ceballos K, **Franco EL**, Coldman AJ, Ogilvie GS, Krajden M. Comparison of the Roche cobas® 4800 and Digene Hybrid Capture® 2 HPV tests for primary cervical cancer screening in the HPV FOCAL trial. *BMC Cancer*. 2015 Dec 16;15:968. doi: 10.1186/s12885-015-1959-5.
5. Richardson LA, El-Zein M, Ramanakumar AV, Ratnam S, Sangwa-Lugoma G, Longatto-Filho A, Cardoso MA, Coutlée F, **Franco EL**; PEACHS (Pap Efficacy After Cervical HPV Status) Study Consortium. HPV DNA testing with cytology triage in cervical cancer screening: Influence of revealing HPV infection status. *Cancer Cytopathol*. 2015 Dec;123(12):745-54. doi: 10.1002/ncy.21596. Epub 2015 Jul 31.
6. Lemieux-Mellouki P, Drolet M, Brisson J, **Franco EL**, Boily MC, Baussano I, Brisson M. Assortative mixing as a source of bias in epidemiological studies of sexually transmitted infections: the case of smoking and human papillomavirus. *Epidemiol Infect*. 2015 Nov 20:1-10.
7. Trottier H, Mayrand MH, Baggio ML, Galan L, Ferenczy A, Villa LL, **Franco EL**; Ludwig-McGill Cohort Study Group. Risk of Human Papillomavirus (HPV) Infection and Cervical Neoplasia after Pregnancy. *BMC Pregnancy Childbirth*. 2015 Oct 7;15:244. doi:

- 10.1186/s12884-015-0675-0.
8. Jit M, **Franco E**, Jha P. What makes an eLife paper in epidemiology and global health? *Elife*. 2015 Oct 7;4. doi: 10.7554/eLife.11326. PubMed PMID: 26445351;
  9. **Franco EL**, Shinder GA, Tota JE, Isidean SD. An elusive low-hanging fruit for public health: gun violence prevention. *Prev Med*. 2015 Oct;79:1-2. doi: 10.1016/j.ypmed.2015.06.008. Epub 2015 Jun 23.
  10. **Franco EL**, Shinder GA, Tota JE, Isidean SD. Sobering realizations in cancer prevention and screening and their lessons. *Prev Med*. 2015 Jul;76:129-31. doi: 10.1016/j.ypmed.2015.04.014. Epub 2015 Apr 29
  11. Coldman AJ, Phillips N, van Niekerk D, Smith L, Krajden M, Cook D, Quinlan DJ, Ehlen T, Miller D, Stuart GC, Peacock S, Elwood Martin R, **Franco EL**, Ogilvie G. Projected Impact of HPV and LBC Primary Testing on Rates of Referral for Colposcopy in a Canadian Cervical Cancer Screening Program. *J Obstet Gynaecol Can*. 2015 May;37(5):412-20.
  12. Lowy DR, Herrero R, Hildesheim A; **Participants in the IARC/NCI workshop** on Primary Endpoints for Prophylactic HPV Vaccine Trials. Primary endpoints for future prophylactic human papillomavirus vaccine trials: towards infection and immunobridging. *Lancet Oncol*. 2015 May;16(5):e226-33. doi: 10.1016/S1470-2045(15)70075-6.
  13. Bennett R, Cerigo H, Coutlée F, Roger M, **Franco EL**, Brassard P. Incidence, persistence, and determinants of human papillomavirus infection in a population of Inuit women in northern Quebec. *Sex Transm Dis*. 2015 May;42(5):272-8. doi: 10.1097/OLQ.0000000000000272.
  14. Monsonego J, Cox JT, Behrens C, Sandri M, **Franco EL**, Yap PS, Huh W. Prevalence of high-risk human papilloma virus genotypes and associated risk of cervical precancerous lesions in a large U.S. screening population: data from the ATHENA trial. *Gynecol Oncol*. 2015 Apr;137(1):47-54. doi: 10.1016/j.ygyno.2015.01.551. Epub 2015 Feb 8.
  15. Louvanto K, **Franco EL**, Ramanakumar AV, Vasiljević N, Scibior-Bentkowska D, Koushik A, Cuzick J, Coutlée F, Lorincz AT; Biomarkers of Cervical Cancer Risk Study Team. Methylation of viral and host genes and severity of cervical lesions associated with human papillomavirus type 16. *Int J Cancer*. 2015 Mar 15;136(6):E638-45. doi: 10.1002/ijc.29196. Epub 2014 Sep 19.
  16. Santos F, Dragomir A, Kassouf W, **Franco EL**, Aprikian A. Predictors of preoperative delays before radical cystectomy for bladder cancer in Quebec, Canada: a population-based study. *BJU Int*. 2015 Mar;115(3):389-96. doi: 10.1111/bju.12742. Epub 2014 Jul 27.
  17. Santos F, Dragomir A, Kassouf W, **Franco E**, Aprikian A. Urologist referral delay and its impact on survival after radical cystectomy for bladder cancer. *Curr Oncol*. 2015 Feb;22(1):e20-6. doi: 10.3747/co.22.2052.
  18. Tota JE, Ramanakumar AV, Villa LL, Richardson H, Burchell AN, Koushik A, Mayrand MH, Coutlée F, **Franco EL**. Evaluation of human papillomavirus type replacement postvaccination must account for diagnostic artifacts: masking of HPV52 by HPV16 in anogenital specimens. *Cancer Epidemiol Biomarkers Prev*. 2015 Jan;24(1):286-90. doi: 10.1158/1055-9965.EPI-14-0566. Epub 2014 Oct 2.
  19. Isidean SD, Tota JE, Gagnon JA, **Franco EL**. Human papillomavirus vaccines: key factors in planning cost-effective vaccination programs. *Expert Rev Vaccines*. 2015 Jan;14(1):119-33. doi: 10.1586/14760584.2015.964213. Epub 2014 Sep 30.



20. Gauthier B, Coutlée F, **Franco EL**, Brassard P. Human papillomavirus variants among Inuit women in northern Quebec, Canada. *Int J Circumpolar Health*. 2015 Dec 9;74:29482. doi: 10.3402/ijch.v74.29482
21. Meguerditchian A, Miller WH, Aprikian A, Batist G, Prchal J, **Franco E**, Benaroya. The Rossy Cancer Network: Building platforms for advancing knowledge in cancer care quality improvement. *Oncology Exchange* 14: 8-11, 2015.
22. **Franco EL**. Perfect is the enemy of good: Going to the war on cancer with less evidence than we could have. *Epidemiologic Methods* 4: 23-28, 2015.

### **Carolyn Freeman**

1. Wang D, Zhang Q, Eisenberg B, Kane J, Li A, Lucas D, Petersen I, DeLaney T, **Freeman C**, Trotti A, Hitchcock Y, Bedi M, Singh A, Dundas G, Kirsch D. Significant reduction of late toxicities in extremity sarcoma patients treated with image-guided radiotherapy to a reduced target volume. *J Clin Oncol*. 2015 Feb 9. pii: JCO.2014.58.5828. [Epub ahead of print]
2. Schiavia A, Jacob Lavigne J, Turcotte R, Kasprzak L, Dumas N, Chong G, **Freeman C**, Alameldin M, Galiatsatos P, Palma L, Foulkes W. Using a family history questionnaire to identify patients at high risk for familial sarcoma. *Current Oncology* 2015;22:317-325. doi: 10.3747/co.22.2588. PMID:26628864
3. Vallières, M., **Freeman, C**, Skamene, S.R., El Naqa, I. A radiomics model from joint FDG-PET and MR texture features for the prediction of lung metastases in soft-tissue sarcomas of the extremities. *Physics in Medicine and Biology* 2015;60: 5471. Selected “Editor’s Choice”
4. Toltz, A, Shin, N, Mitrou, E, Laude, C, **Freeman, C**, Seuntjens, J, Parker, W, Roberge, D. Late radiation toxicity in Hodgkin lymphoma patients: proton therapy’s potential. *Journal of Applied Clinical Medical Physics* 2015;16:167-178
5. Li A, Chen X, Zhang Q, Kirsch D, Petersen I, DeLaney T, **Freeman C**, Trotti A, Hitchcock Y, Wang D. Margin reduction from IGRT for soft-tissue sarcoma: secondary analysis of RTOG 0630 results. *Practical Radiation Oncology* 2015: pii: S1879-8500(15)00411-7. doi: 10.1016/j.prro.2015.11.012. [Epub ahead of print] PMID: 26852173
6. Skamene S, Abish S, Mitchell D, **Freeman C**. Radiotherapy is Important for Local Control at Primary and Metastatic Sites in Pediatric Rhabdomyosarcoma. *Cureus* 2015;PMID:26719831[PubMed] PMCID:PMC4689588
7. Charpentier A-M, **Freeman C**, Roberge D, Rousseau P. Radiotherapy. In *Pediatric Neuro-oncology*. Eds. Scheinemann and Bouffet. Springer. Chapter 18, 2015.
8. Rodriguez-Galindo C, Charpentier A-M, **Freeman C**. Retinoblastoma. In *Gunderson’s Clinical Radiation Oncology* 4th Ed, Chapter 69, 2015.

### **Vincent Giguere**

1. Yuk JM, Kim TS, Kim SY, Lee HM, Han J, Dufour CR, Kim JK, Jin HS, Yang CS, Park KS, Lee CH, Kim JM, Kweon GR, Choi HS, Vanacker JM, Moore DD, **Giguère V**, Jo EK. Orphan Nuclear Receptor  $ERR\alpha$  Controls Macrophage Metabolic Signaling and A20 Expression to Negatively Regulate TLR-Induced Inflammation. *Immunity*. 2015 Jul 21;43(1):80-91. doi: 10.1016/j.immuni.2015.07.003.
2. Tam IS, **Giguère V**. There and back again: The journey of the estrogen-related receptors in the cancer realm. *J Steroid Biochem Mol Biol*. 2016 Mar;157:13-9. doi: 10.1016/j.jsbmb.2015.06.009. Epub 2015 Jul 4.
3. **Giguère V**. Editorial: What's in a Name, or the Impact of Misnomers in Endocrine Research.

Mol Endocrinol. 2015 Jun;29(6):789-90. doi: 10.1210/me.2015-1119.

4. Wang T, McDonald C, Petrenko NB, Leblanc M, Wang T, **Giguere V**, Evans RM, Patel VV, Pei L. Estrogen-related receptor  $\alpha$  (ERR $\alpha$ ) and ERR $\gamma$  are essential coordinators of cardiac metabolism and function. *Mol Cell Biol*. 2015 Apr;35(7):1281-98. doi: 10.1128/MCB.01156-14.
5. Audet-Walsh É, **Giguère V**. The multiple universes of estrogen-related receptor  $\alpha$  and  $\gamma$  in metabolic control and related diseases. *Acta Pharmacol Sin*. 2015 Jan;36(1):51-61. doi: 10.1038/aps.2014.121. Epub 2014 Dec 15. Review.

### **Philip Gordon**

1. Kleiman A, Al-Khamis A, Farsi A, Kezouh A, Vuong T, **Gordon PH**, Vasilevsky CA, Morin N, Faria J, Ghitulescu G, Boutros M. Normalization of CEA Levels Post-Neoadjuvant Therapy is a Strong Predictor of Pathologic Complete Response in Rectal Cancer. *J Gastrointest Surg*. 2015 Jun;19(6):1106-12. doi: 10.1007/s11605-015-2814-3. Epub 2015 Apr 10.

### **Walter Gotlieb**

1. Singh SS, Scott S, Bougie O, Leyland N; SOGC Clinical Practice-Gynaecology Committee, Leyland N, Wolfman W, Allaire C, Awadalla A, Bullen A, Burnett M, Goldstein S, Lemyre M, Marcoux V, Potestio F, Rittenberg D, Singh SS, Yeung G, Hoskins P, Miller D, **Gotlieb W**, Bernardini M, Hopkins L. Technical update on tissue morcellation during gynaecologic surgery: its uses, omplications, and risks of unsuspected malignancy. *J Obstet Gynaecol Can*. 2015 Jan;37(1):68-81.
2. Kiely DJ, **Gotlieb WH**, Jardon K, Lau S, Press JZ. Advancing surgical simulation in gynecologic oncology: robotic dissection of a novel pelvic lymphadenectomy model. *Simul Healthc*. (2015) 10: 38-42
3. Zeng XZ, Lavoue V, Lau S, Press, JX, Abitbol J, Gotlieb R, How J, Wang Y, **Gotlieb WH**. Outcome of robotic surgery for endometrial cancer as a function of patient age. *Int J Gynecol Cancer* (2015) May 25: 637-44.
4. How JA, Abitbol J, Lau S, **Gotlieb WH**, Abenheim HA. The impact of Qualitative Research on Gynaecologic Oncology Guidelines. *J Obstet Gynaecol Can*. (2015) 37: 138-44
5. Rabinovich A, Ramankumar AV, Lau S, **Gotlieb WH**. Prolonged Pegylated Liposomal Doxorubicin treatment for recurrent pelvic cancers. *Acta Obstetrica et Gynecologica Scandinavica* (2015) Apr Epub
6. Hoskins P, Fung-Kee-Fung M, Miller D, **Gotlieb WH**. Time for a level playing field. Inequalities in regulatory approval processes: The example of bevacizumab in epithelial ovarian cancer. *J.Clin.Oncol*. (2015) Apr Epub
7. How J, **Gotlieb WH**, Press JZ, Abitbol J, Pelmus M, Ferenczy A, Probst R, Gotlieb R, Brin S, Lau S. Comparing indocyanine green, technetium, and blue dye for sentinel lymph node mapping in endometrial cancer. *Gynecol Oncol*. (2015) 137: 436-443
8. Kiely DJ, **Gotlieb WH**, Lau S, Zeng X, Samouelian V, Ramankumar AV, Zakrzewski H, Brin S, Fraser SA, Korsieporn P, Drudi L, Press JZ. Virtual-reality robotic surgery simulation curriculum to teach robotic suturing: a randomized controlled trial". *Journal of Robotic Surgery* (2015) 9: 179-86
9. Rabinovich A, Bernard L, Niazi TM, Ramankumar AV, **Gotlieb WH**, Lau S, Bahoric B. Para-aortic and pelvic radiotherapy, an effective and safe treatment in advanced-stage uterine cancer. *Anticancer Res* (2015) May; 35(5) 2893-900

10. Cormier B, Rozenholc AT, **Gotlieb W**, Plante M, Giede C, Communities of Practice (CoP) Group of the Society of Gynecologic Oncology of Canada (GOC). Sentinel lymph node procedure in endometrial cancer: A systematic review and proposal for standardization of future research *Gynecol Oncol* (2015) 138: 479-85
11. Zakhari A, Czuzoj-Shulman N, Spence AR, **Gotlieb WH**, Abenhaim HA Laparoscopic and robotic-assisted hysterectomy for uterine cancer: a comparison of costs and complications. *Am J Obstet Gynecol* (2015) Jul 15 Epub ahead of print
12. Marques M, Beauchamp MC, Fleury H, Laskov I, Qiang S, Pelmus M, Mes-Masson AM, **Gotlieb WH**, Witcher M. Chemotherapy reduces PARP1 in solid tumors: implications for future clinical trials involving PARP inhibitors. *BMC Cancer* (2015) 13: 217
13. Amin O, Beauchamp MC, Abou Nader P, Laskov I, Iqbal S, Philip CA, Yasmeen A, **Gotlieb WH**. Suppression of Homologous Recombination by insulin-like growth factor-1 inhibition sensitizes cancer cells to PARP inhibitors. *BMC Cancer* (2015) 15: 817
14. Oza AM, Cook AD, Pfisterer J et al. Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON 7): overall survival results of a phase 3 randomized trial. *Lancet Oncol* (2015) 16: 928-36
15. Rabinovich A, Bernard L, Ramanakumar AV, Stroian G, **Gotlieb WH**, Lau S, Bahoric B. Para-aortic and pelvic extended-field radiotherapy for advanced-stage uterine cancer: dosimetric and toxicity comparison between the four-field box and intensity-modulated techniques. *Curr Oncol*. 2015 Dec;22(6):405-1.
16. Laskov I, **Gotlieb WH**, Rabinovich A Role of Laparoscopic and Robotic Surgery in Endometrial Cancer – The Inevitable Evolution. In “Uterine Cancer: Diagnosis & Management (2015) Springer Verlag. E. Dinesh Editor
17. How J, **Gotlieb WH**. Sentinel lymph nodes evaluation in endometrial cancer. In “Uterine Cancer: Diagnosis & Management (2015) Springer Verlag. E. Dinesh Editor
18. Huang LN, Lau S, **Gotlieb WH**. Poor outcomes after conservative management for low-grade apparent early-stage endometrial cancer. *Obstet Gynecol* (2015) May 125: 106
19. J.Abitbol, **Gotlieb WH**. Robotic Surgery in gynecologic oncology: where do we stand? In “Reproductive Geneeskunde, Gynaecologie en Obstetrie” (2015) DCHG Med.Comm, Haarlem (The Netherland) E. Slager Editor, p1142-50

### **Celia Greenwood**

1. PN Taylor, E Porcu, S Chew, PJ Campbell, M Traglia, SJ Brown, BH Mullin, HA Shihab, J Min, J Walter, Y Memari, J Huang, MR Barnes, JP Beibly, P Charoen, P Danecek, F Dudbridge, V Forgetta, **CMT Greenwood**, E Grundberg, AD Johnson, J Hui, EM Lim, S McCarthy, D Muddyman, V Panicker, JRB Perry, JT Bell, W Yuan, C Relton, T Gaunt, D Schlessinger, G Abecasis, F Cucca, GL Surdulescu, W Woltersdorf, E. Zeggini, HF Zheng, D Toniolo, CM Dayan, S Naitza, JP Walsh, TD Spector, GD Smith, R Durbin, JB Richards, S Sanna, N Soranzo, NJ Timpson, SG Wilson and the UK10K Consortium (2015). Whole genome based analysis of thyroid function. *Nature Communications*, 6:5681. doi: 10.1038/ncomms6681
2. Omar S. Ahmad, John A Morris, Muhammad Mujammami, Vincenzo Forgetta, Rui Li, **Celia MT Greenwood**, George Thanassoulis, James Meigs, Robert Sladek, J. Brent Richards. (2015). A Mendelian randomization study of the effect of type-2 diabetes on coronary heart disease. *Nature Communications*, 6:7060. doi: 10.1038/ncomms8060.

3. Michelle Cotterchio, Beth Lowcock, Mathieu Lemire, **Celia M T Greenwood**, Steven Gallinger, Tom Hudson (2015). Association between variants in atopy-related immunologic candidate genes and pancreatic cancer risk. *PLoS ONE* 10(5):e0125273. doi: 10.1371/journal.pone.0125273.
4. K Walter\*, J Min\*, J Huang\*, L Crooks\*, Y Memari, S McCarthy, JRB Perry, C Xu, M Futema, D Lawson, V Iotchkova, S Schiffels, A Hendricks, P Danecek, R Li, J Floyd, I Barroso, SE Humphries, ME Hurles, E Zeggini, JC Barrett, V Plagnol, JB Richards, **C Greenwood**, N Timpson, R Durbin, N Soranzo (2015). The UK10K project: rare variants in health and disease. *Nature*, 526(7571):82-90.
5. HF Zheng\*, V Forgetta\*, YH Hsu\*, K Estrada\*, A Rosello-Diez\*, PJ Leo\*, CL Dahia\*, KH Park-Min\*, JH Tobias\*, C Kooperberg\*, A Kleinman, U Styrkarsdottir, CT Liu, C Uggla, DS Evans, CM Nielson, K Walter, U Pettersson-Kymmer, S McCarthy, J Eriksson, T Kwan, M Jhamai, K Trajanoska, Y Memari, J Min, J Huang, P Danecek, B Wilmot, R Li, WC Chou, LE Mokry, 113 co-authors, RD Jackson†, DW Rowe†, CA Loomis†, DM Evans†, CL Ackert-Bicknell†, AL Joyner†, EL Duncan†, DP Kiel†, F Rivadeneira†, JB Richards† for the **GEFOS and UK10K Consortia**. \* and † denote equal contribution (2015). Whole-genome sequence-based identification of EN1 as a determinant of bone density and fracture. *Nature*, 526(7571):112-117.
6. LE Mokry, S Ross, OS Ahmad, V Forgetta, G Davey-Smith, A Leong, **CMT Greenwood**, G Thanassoulis, JB Richards. (2015). Vitamin D and risk of Multiple Sclerosis: A Mendelian Randomization Study. *PLOS Medicine*. 12(8):e1001866. doi: 10.1371/journal.pmed.1001866.
7. 12. Castellsagué E, Liu J, Volenik A, Giroux S, Gagné R, Maranda B, Roussel-Jobin A, Latreille J, Laframboise R, Palma L, Kasprzak L, Marcus VA, Breguet M, Nolet S, El-Haffaf Z, Australie K, Gologan A, Aleynikova O, Oros-Klein K, **Greenwood C**, Mes-Masson AM, Provencher D, Tischkowitz M, Chong G, Rousseau F, Foulkes WD. (2015). Characterization of a novel founder MSH6 mutation causing Lynch syndrome in the French Canadian population. *Clin Genet*. 87(6):536-42. doi: 10.1111/cge.12526.
8. **CMT Greenwood**, C Xu, A Ciampi. (2015). Significance thresholds for rare variant signals. 169-183. Assessing rare variation in complex traits: design and analysis of genetic studies. Editors: Andrew Morris, Eleftheria Zeggini. Springer, New York. DOI: 10.1007/978-1-4939-2824-8. (book chapter)
9. Hudson M, Colmegna I, Bernatsky S, Baron M, Klein Oros K, Pastinen T, **Greenwood C** (2015). Novel approaches to discovery of biomarkers in rheumatoid arthritis. July 28, 2015, *Arthritis Rheumatol*. Doi: 10.1002/art.39189. (published correspondence)

### **Melissa Henry**

1. **Henry M**, Bdira A, Cherba M, Lambert S, Carnevale FA, MacDonald C, Hier M, Zeitouni A, Kost K, Mlynarek A, Black M, Rosberger Z, Frenkiel S. Recovering function and surviving treatments are primary motivators for health behavior change in patients with head and neck cancer: Qualitative focus group study. *Palliat Support Care*. 2015 Nov 23:1-12. [Epub ahead of print]
2. MacKinnon CJ, Smith NG, **Henry M**, Milman E, Chochinov HM, Körner A, Berish M, Farrace AJ, Liarikos N, Cohen SR. Reconstructing Meaning with Others in Loss: A Feasibility Pilot Randomized Controlled Trial of a Bereavement Group. *Death Stud*. 2015;39(7):411-21. doi: 10.1080/07481187.2014.958628. Epub 2015 Feb 12.

**Michael Hier**

1. Henry M, Bdira A, Cherba M, Lambert S, Carnevale FA, MacDonald C, **Hier M**, Zeitouni A, Kost K, Mlynarek A, Black M, Rosberger Z, Frenkiel S. Recovering function and surviving treatments are primary motivators for health behavior change in patients with head and neck cancer: Qualitative focus group study. *Palliat Support Care*. 2015 Nov 23:1-12. [Epub ahead of print]
2. Madana J, Laliberté F, Morand GB, Yolmo D, Black MJ, Mlynarek AM, **Hier MP**. Computerized tomography based tumor-thickness measurement is useful to predict postoperative pathological tumor thickness in oral tongue squamous cell carcinoma. *J Otolaryngol Head Neck Surg*. 2015 Nov 16;44:49. doi: 10.1186/s40463-015-0089-z.
3. Roskies M, Liu X, **Hier MP**, Payne RJ, Mlynarek A, Forest V, Levental M, Forghani R. 3-phase dual-energy CT scan as a feasible salvage imaging modality for the identification of non-localizing parathyroid adenomas: a prospective study. *J Otolaryngol Head Neck Surg*. 2015 Oct 31;44:44. doi: 10.1186/s40463-015-0098-y.
4. Madana J, Morand GB, Alrasheed A, Gabra N, Laliberté F, Barona-Lleó L, Yolmo D, Black MJ, Sultanem K, **Hier MP**. Clinical parameters predicting development of pulmonary malignancies in patients treated for head and neck squamous cell carcinoma. *Head Neck*. 2015 Oct 30. doi: 10.1002/hed.24210. [Epub ahead of print]
5. Al-Bader A, Zawawi F, Singer Z, Mlynarek A, Hier M, Tamilia M, Payne R. Preoperative TSH and thyroglobulin levels: would it predict thyroid cancer? *Otolaryngol Pol*. 2015;69(3):21-5. doi: 10.5604/00306657.1156331.
6. Kay-Rivest E, Mitmaker E, Payne RJ, **Hier MP**, Mlynarek AM, Young J, Forest VI. Preoperative vocal cord paralysis and its association with malignant thyroid disease and other pathological features. *J Otolaryngol Head Neck Surg*. 2015 Sep 11;44:35. doi: 10.1186/s40463-015-0087-1.
7. Schwartz RN, Payne RJ, Forest VI, **Hier MP**, Fanous A, Vallée-Gravel C. The relationship between upper airway collapse and the severity of obstructive sleep apnea syndrome: a chart review. *J Otolaryngol Head Neck Surg*. 2015 Sep 4;44:32. doi: 10.1186/s40463-015-0086-2.
8. da Silva SD, Marchi FA, Xu B, Bijian K, Alobaid F, Mlynarek A, Rogatto SR, **Hier M**, Kowalski LP, Alaoui-Jamali MA. Predominant Rab-GTPase amplicons contributing to oral squamous cell carcinoma progression to metastasis. *Oncotarget*. 2015 Sep 8;6(26):21950-63.
9. Ibrahim B, Forest VI, **Hier M**, Mlynarek AM, Caglar D, Payne RJ. Completion thyroidectomy: predicting bilateral disease. *J Otolaryngol Head Neck Surg*. 2015 Jun 16;44:23. doi: 10.1186/s40463-015-0076-4.
10. Madana J, Morand GB, Barona-Lleo L, Black MJ, Mlynarek AM, **Hier MP**. A survey on pulmonary screening practices among otolaryngology-head & neck surgeons across Canada in the post treatment surveillance of head and neck squamous cell carcinoma. *J Otolaryngol Head Neck Surg*. 2015 Feb 4;44:5. doi: 10.1186/s40463-015-0057-7.
11. Varshney R, Forest VI, Mascarella MA, Zawawi F, Rochon L, **Hier MP**, Mlynarek A, Tamilia M, Payne RJ. The McGill thyroid nodule score - does it help with indeterminate thyroid nodules? *J Otolaryngol Head Neck Surg*. 2015 Feb 3;44:2. doi: 10.1186/s40463-015-0058-6.

### Tarek Hijal

1. Tiberi D, **Hijal T**, Yassa M. Current status of hypofractionated external beam radiotherapy for early-stage breast cancer. *Cancer Radiother.* 2015 Oct;19(6-7):426-30. doi: 10.1016/j.canrad.2015.05.003. Epub 2015 Aug 14. Review. French.

### Vera Hirsh

1. Paz-Ares L, **Hirsh V**, Zhang L, de Marinis F, Yang JC, Wakelee HA, Seto T, Wu YL, Novello S, Juhász E, Arén O, Sun Y, Schmelter T, Ong TJ, Peña C, Smit EF, Mok TS. Monotherapy Administration of Sorafenib in Patients With Non-Small Cell Lung Cancer (MISSION) Trial: A Phase III, Multicenter, Placebo-Controlled Trial of Sorafenib in Patients with Relapsed or Refractory Predominantly Nonsquamous Non-Small-Cell Lung Cancer after 2 or 3 Previous Treatment Regimens. *J Thorac Oncol.* 2015 Dec;10(12):1745-53. doi: 10.1097/JTO.0000000000000693.
2. Scagliotti G, von Pawel J, Novello S, Ramlau R, Favaretto A, Barlesi F, Akerley W, Orlov S, Santoro A, Spigel D, **Hirsh V**, Shepherd FA, Sequist LV, Sandler A, Ross JS, Wang Q, von Roemeling R, Shuster D, Schwartz B. Phase III Multinational, Randomized, Double-Blind, Placebo-Controlled Study of Tivantinib (ARQ 197) Plus Erlotinib Versus Erlotinib Alone in Previously Treated Patients With Locally Advanced or Metastatic Nonsquamous Non-Small-Cell Lung Cancer. *J Clin Oncol.* 2015 Aug 20;33(24):2667-74. doi: 10.1200/JCO.2014.60.7317. Epub 2015 Jul 13.
3. **Hirsh V**. Next-Generation Covalent Irreversible Kinase Inhibitors in NSCLC: Focus on Afatinib. *BioDrugs.* 2015 Jun;29(3):167-83. doi: 10.1007/s40259-015-0130-9.
4. Ellis PM, Leigh NB, **Hirsh V**, Reaume MN, Blais N, Wierzbicki R, Sadrolhefazi B, Gu Y, Liu D, Pilz K, Chu Q. A Randomized, Open-Label Phase II Trial of Volasertib as Monotherapy and in Combination With Standard-Dose Pemetrexed Compared With Pemetrexed Monotherapy in Second-Line Treatment for Non-Small-Cell Lung Cancer. *Clin Lung Cancer.* 2015 Nov;16(6):457-65. doi: 10.1016/j.clcc.2015.05.010. Epub 2015 Jun 2.
5. Langer CJ, **Hirsh V**, Okamoto I, Lin FJ, Wan Y, Whiting S, Ong TJ, Renschler MF, Botteman MF. Survival, quality-adjusted survival, and other clinical end points in older advanced non-small-cell lung cancer patients treated with albumin-bound paclitaxel. *Br J Cancer.* 2015 Jun 30;113(1):20-9. doi: 10.1038/bjc.2015.181. Epub 2015 Jun 2.
6. Ramalingam S, Goss G, Rosell R, Schmid-Bindert G, Zaric B, Andric Z, Bondarenko I, Komov D, Ceric T, Khuri F, Samarzija M, Filip E, Ciuleanu T, **Hirsh V**, Wehler T, Spicer J, Salgia R, Shapiro G, Sheldon E, Teofilovici F, Vukovic V, Fennell D. A randomized phase II study of ganetespib, a heat shock protein 90 inhibitor, in combination with docetaxel in second-line therapy of advanced non-small cell lung cancer (GALAXY-1). *Ann Oncol.* 2015 Aug;26(8):1741-8. doi: 10.1093/annonc/mdv220. Epub 2015 May 21.
7. **Hirsh V**. The treatment of metastatic non-small cell lung cancer in a new era of personalized medicine. *Front Oncol.* 2015 Feb 3;5:20. doi: 10.3389/fonc.2015.00020. eCollection 2015. No abstract available.
8. Yang JC, Wu YL, Schuler M, Sebastian M, Popat S, Yamamoto N, Zhou C, Hu CP, O'Byrne K, Feng J, Lu S, Huang Y, Geater SL, Lee KY, Tsai CM, Gorbunova V, **Hirsh V**, Bennouna J, Orlov S, Mok T, Boyer M, Su WC, Lee KH, Kato T, Massey D, Shahidi M, Zazulina V, Sequist LV. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two

randomised, phase 3 trials. *Lancet Oncol.* 2015 Feb;16(2):141-51. doi: 10.1016/S1470-2045(14)71173-8. Epub 2015 Jan 12.

9. Langer CJ, **Hirsh V**, Ko A, Renschler MF, Socinski MA. Weekly nab-paclitaxel in combination with carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: analysis of safety and efficacy in patients with renal impairment. *Clin Lung Cancer.* 2015 Mar;16(2):112-20. doi: 10.1016/j.clcc.2014.09.003. Epub 2014 Sep 30.

### **Kris Jardon**

1. Bourdel N, Cognet S, Canis M, Berdugo O, Botchorishvili R, Rabischong B, **Jardon K**. Laparoscopic Ureteroneocystostomy: Be Prepared! *J Minim Invasive Gynecol.* 2015 Jul-Aug;22(5):827-33. doi: 10.1016/j.jmig.2015.03.019. Epub 2015 Apr 4.
2. Kiely DJ, Gotlieb WH, **Jardon K**, Lau S, Press JZ. Advancing surgical simulation in gynecologic oncology: robotic dissection of a novel pelvic lymphadenectomy model. *Simul Healthc.* 2015 Feb;10(1):38-42. doi: 10.1097/SIH.0000000000000054.

### **Nathalie Johnson**

1. Morin RD, Assouline S, Alcaide M, Mohajeri A, Johnston RL, Chong L, Grewal J, Yu S, Fornika D, Bushell K, Nielsen TH, Petrogiannis-Halotis T, Crump M, Tosikyan A, Grande BM, MacDonald D, Rousseau C, Bayat M, Sesques P, Froment R, Albuquerque M, Monczak Y, Oros KK, Greenwood C, Riazalhosseini Y, Arseneault M, Camlioglu E, Constantin A, Pan-Hammarstrom Q, Peng R, Mann KK, **Johnson NA**. Genetic Landscapes of Relapsed and Refractory Diffuse Large B-Cell Lymphomas. *Clin Cancer Res.* 2015 Dec 8. [Epub ahead of print]
2. Chan FC, Telenius A, Healy S, Ben-Neriah S, Mottok A, Lim R, Drake M, Hu S, Ding J, Ha G, Scott DW, Kridel R, Bashashati A, Rogic S, **Johnson N**, Morin RD, Rimsza LM, Sehn L, Connors JM, Marra MA, Gascoyne RD, Shah SP, Steidl C. An RCOR1 loss-associated gene expression signature identifies a prognostically significant DLBCL subgroup. *Blood.* 2015 Feb 5;125(6):959-66. doi: 10.1182/blood-2013-06-507152. Epub 2014 Nov 13.

### **Petr Kavan**

1. Xu Y, Stavrides-Eid M, Baig A, Cardoso M, Rho YS, Shams WM, Mamo A, **Kavan P**. Quantifying treatment delays in adolescents and young adults with cancer at McGill University. *Curr Oncol.* 2015 Dec;22(6):e470-7. doi: 10.3747/co.22.2724.
2. McLean J, Rho YS, Kuruba G, Mamo A, Gilabert M, Kavan T, Panasci L, Melnychuk D, Batist G, **Kavan P**. Clinical Practice Patterns in Chemotherapeutic Treatment Regimens for Metastatic Colorectal Cancer. *Clin Colorectal Cancer.* 2015 Oct 21. pii: S1533-0028(15)00118-8. doi: 10.1016/j.clcc.2015.10.003. [Epub ahead of print]
3. Pettigrew M, **Kavan P**, Surprenant L, Lim HJ. Comparative net cost impact of the utilization of panitumumab versus cetuximab for the treatment of patients with metastatic colorectal cancer in Canada. *J Med Econ.* 2016 Feb;19(2):135-47. doi: 10.3111/13696998.2015.1105230. Epub 2015 Nov 11.
4. Alshami J, Guiot MC, Owen S, **Kavan P**, Gibson N, Solca F, Cseh A, Reardon DA, Muanza T. Afatinib, an irreversible ErbB family blocker, with protracted temozolomide in recurrent glioblastoma: a case report. *Oncotarget.* 2015 Oct 20;6(32):34030-7. doi: 10.18632/oncotarget.5297.

5. Rho YS, Barrera I, Metrakos P, **Kavan P**. Complete Resolution of Metastatic Gallbladder Cancer after Standard Gemcitabine-Cisplatin Combination Therapy. *Cureus*. 2015 Dec 17;7(12):e415. doi: 10.7759/cureus.415.
6. Easaw JC, Shea-Budgell MA, Wu CM, Czaykowski PM, Kassis J, Kuehl B, Lim HJ, MacNeil M, Martinusen D, McFarlane PA, Meek E, Moodley O, Shivakumar S, Tagalakis V, Welch S, **Kavan P**. Canadian consensus recommendations on the management of venous thromboembolism in patients with cancer. Part 1: prophylaxis. *Curr Oncol*. 2015 Apr;22(2):133-43. doi: 10.3747/co.22.2586.
7. Easaw JC, Shea-Budgell MA, Wu CM, Czaykowski PM, Kassis J, Kuehl B, Lim HJ, MacNeil M, Martinusen D, McFarlane PA, Meek E, Moodley O, Shivakumar S, Tagalakis V, Welch S, **Kavan P**. Canadian consensus recommendations on the management of venous thromboembolism in patients with cancer. Part 2: treatment. *Curr Oncol*. 2015 Apr;22(2):144-55. doi: 10.3747/co.22.2587.
8. Smith AL, Bascuñana C, Hall A, Salman A, Andrei AZ, Volenik A, Rothenmund H, Ferland D, Lamoussenary D, Kamath AS, Amre R, Caglar D, Gao ZH, Haegert DG, Kanber Y, Michel RP, Omeroglu-Altinel G, Asselah J, Bouganim N, **Kavan P**, Arena G, Barkun J, Chaudhury P, Gallinger S, Foulkes WD, Omeroglu A, Metrakos P, Zogopoulos G. Establishing a clinic-based pancreatic cancer and periampullary tumour research registry in Quebec. *Curr Oncol*. 2015 Apr;22(2):113-21. doi: 10.3747/co.22.2300.
9. Hoffer LJ, Robitaille L, Zakarian R, Melnychuk D, **Kavan P**, Agulnik J, Cohen V, Small D, Miller WH Jr. High-dose intravenous vitamin C combined with cytotoxic chemotherapy in patients with advanced cancer: a phase I-II clinical trial. *PLoS One*. 2015 Apr 7;10(4):e0120228. doi: 10.1371/journal.pone.0120228. eCollection 2015.
10. Stutz M, Mamo A, Valenti D, Hausvater A, Cabrera T, Metrakos P, Chaudhury P, Steacy G, Garoufalidis E, **Kavan P**. Real-Life Report on Chemoembolization Using DEBIRI for Liver Metastases from Colorectal Cancer. *Gastroenterol Res Pract*. 2015;2015:715102. doi: 10.1155/2015/715102. Epub 2015 Feb 26.
11. Reardon DA, Nabors LB, Mason WP, Perry JR, Shapiro W, **Kavan P**, Mathieu D, Phuphanich S, Cseh A, Fu Y, Cong J, Wind S, Eisenstat DD; BI 1200 36 Trial Group and the Canadian Brain Tumour Consortium. Phase I/randomized phase II study of afatinib, an irreversible ErbB family blocker, with or without protracted temozolomide in adults with recurrent glioblastoma. *Neuro Oncol*. 2015 Mar;17(3):430-9. doi: 10.1093/neuonc/nou160. Epub 2014 Aug 19.

### John Kildea

1. Maglieri R, Licea A, Evans M, Seuntjens J, **Kildea J**. Measuring neutron spectra in radiotherapy using the nested neutron spectrometer. *Med Phys*. 2015 Nov;42(11):6162-9. doi: 10.1118/1.4931963.

### Neil Kopek

1. Lee S, Ybarra N, Jeyaseelan K, Faria S, **Kopek N**, Brisebois P, Bradley JD, Robinson C, Seuntjens J, El Naqa I. Bayesian network ensemble as a multivariate strategy to predict radiation pneumonitis risk. *Med Phys*. 2015 May;42(5):2421-30. doi: 10.1118/1.4915284.
2. Offersen BV, Boersma LJ, Kirkove C, Hol S, Aznar MC, Biete Sola A, Kirova YM, Pignol JP, Remouchamps V, Verhoeven K, Weltens C, Arenas M, Gabrys D, **Kopek N**, Krause M, Lundstedt D, Marinko T, Montero A, Yarnold J, Poortmans P. ESTRO consensus guideline



on target volume delineation for elective radiation therapy of early stage breast cancer. *Radiother Oncol.* 2015 Jan;114(1):3-10. doi: 10.1016/j.radonc.2014.11.030. Epub 2015 Jan

#### **Antonis Koromilas**

1. **Koromilas AE** (2015) “Roles of the translation initiation factor eIF2 $\alpha$  serine 51 phosphorylation in cancer formation and treatment.” *Biochim Biophys Acta* 1849:871-80
2. Rajesh K, Krishnamoorthy J, Kazimierczak U, Tenkeria C, Papadakis AI, Wang S, Huang S, **Koromilas AE** (2015) “eIF2 $\alpha$  phosphorylation at serine 51 determines the cell fate decisions of Akt in response to oxidative stress.” *Cell Death Disease* 6:e1591
3. Wang S, Patsis C, **Koromilas AE** (2015) “Stat1 stimulates cap-independent mRNA translation to inhibit cell proliferation and promote survival in response to anti-tumor drugs.” *Proc Natl Acad Sci U S A.* 112:E2149-55
4. Wang S, **Koromilas AE** (2015) The translational effect of STAT1-mediated tumor suppression and its implications in anti-tumor treatments. *Molecular and Cellular Oncology* DOI:10.1080/23723556.2015.1055049
5. Tenkerian C, Krishnamoorthy JL, Mounir Z, Kazimierczak U, Khoutorsky A, Staschke KA, Kristof AS, Wang S, Hatzoglou M, **Koromilas AE** (2015) mTORC2 balances Akt activation and eIF2 $\alpha$  serine 51 phosphorylation to promote survival under stress. *Mol Cancer Res.* **13**:1377-88

#### **Bernard Lapointe**

1. Hospital Based Palliative Care. In the textbook *Death, Dying and Bereavement, Contemporary perspectives, institutions, and practices.* Published by Springer.

#### **Susie Lau**

1. Kiely DJ, Gotlieb WH, **Lau S**, Zeng X, Samouelian V, Ramanakumar AV, Zakrzewski H, Brin S, Fraser SA, Korsiepor P, Drudi L, Press JZ. Virtual reality robotic surgery simulation curriculum to teach robotic suturing: a randomized controlled trial. *J Robot Surg.* 2015 Sep;9(3):179-86. doi: 10.1007/s11701-015-0513-4. Epub 2015 May 16.
2. Altman AD, Ferguson SE, Atenafu EG, Köbel M, McAlpine JN, Panzarella T, **Lau S**, Gien LT, Gilks B, Clarke B, Cameron A, Nelson G, Han G, Samouëlian V, Ho TC, Louie K, Bernardini MQ. Canadian high risk endometrial cancer (CHREC) consortium: analyzing the clinical behavior of high risk endometrial cancers. *Gynecol Oncol.* 2015 Nov;139(2):268-74. doi: 10.1016/j.ygyno.2015.09.001. Epub 2015 Sep 6.
3. Rabinovich A, Bernard L, Niazi TM, Ramanakumar AV, Gotlieb WH, **Lau S**, Bahoric B. Para-aortic and Pelvic Radiotherapy, an Effective and Safe Treatment in Advanced-stage Uterine Cancer. *Anticancer Res.* 2015 May;35(5):2893-900.
4. Rabinovich A, Ramanakumar AV, **Lau S**, Gotlieb WH. Prolonged pegylated liposomal doxorubicin treatment for recurrent pelvic cancers: a feasibility study. *Acta Obstet Gynecol Scand.* 2015 Jul;94(7):776-80. doi: 10.1111/aogs.12642. Epub 2015 Apr 28.
5. How JA, Abitbol J, **Lau S**, Gotlieb WH, Abenhaim HA. The impact of qualitative research on gynaecologic oncology guidelines. *J Obstet Gynaecol Can.* 2015 Feb;37(2):138-44.
6. Zeng XZ, Lavoue V, **Lau S**, Press JZ, Abitbol J, Gotlieb R, How J, Wang Y, Gotlieb WH. Outcome of robotic surgery for endometrial cancer as a function of patient age. *Int J Gynecol Cancer.* 2015 May;25(4):637-44. doi: 10.1097/IGC.0000000000000411.

### Ives Levesque

1. Alonso-Ortiz, E.\*, **Levesque, I. R.** and Pike, G. B. MRI-based myelin water imaging: A technical review. *Magnetic Resonance in Medicine* 73(1): 70–81 (2015).
2. Stikov, N., Boudreau, M., **Levesque, I. R.**, Tardif, C. L., Barral, J. K. and Pike, G. B. On the accuracy of T1 mapping: Searching for common ground. *Magnetic Resonance in Medicine* 73(2): 514–522 (2015).
3. Zhang, T., Pauly, J. M. and **Levesque, I. R.** Accelerating parameter mapping with a locally low rank constraint. *Magnetic Resonance in Medicine* 73(2): 655–661 (2015).

### Sender Liberman

1. Gillis C, Nguyen TH, **Liberman AS**, Carli F. Nutrition adequacy in enhanced recovery after surgery: a single academic center experience. *Nutr Clin Pract.* 2015 Jun;30(3):414-9. doi: 10.1177/0884533614562840. Epub 2014 Dec 29.
2. Lee L, Mata J, Ghitulescu GA, Boutros M, Charlebois P, Stein B, **Liberman AS**, Fried GM, Morin N, Carli F, Latimer E, Feldman LS. Cost-effectiveness of Enhanced Recovery Versus Conventional Perioperative Management for Colorectal Surgery. *Ann Surg.* 2015 Dec;262(6):1026-33. doi: 10.1097/SLA.0000000000001019.

### Carmen Loiselle

1. Rashi C, Wittman T, Tsimicalis A, **Loiselle CG**. Balancing Illness and Parental Demands: Coping With Cancer While Raising Minor Children. *Oncol Nurs Forum.* 2015 Jul;42(4):337-44. doi: 10.1188/15.ONF.337-344.
2. Arbour C, Gélinas C, **Loiselle CG**, Bourgault P. An exploratory study of the bilateral bispectral index for pain detection in traumatic-brain-injured patients with altered level of consciousness. *J Neurosci Nurs.* 2015 Jun;47(3):166-77. doi: 10.1097/JNN.000000000000137.

### Koren Mann

1. AM Bolt, V Sabourin, MF Molina, AM Police, LF Negro Silva, D Plourde, M Lemaire, J Ursini-Siegel, **KK Mann**. Tungsten targets the tumor microenvironment to enhance breast cancer metastasis. *Toxicol Sci.* Jan;143(1):165-77, 2015.
2. T Ebrahimian, D Simon, CA Lemarié, S, Simeone M Heidari, **KK Mann**, S Wassmann, S Lehoux. Absence of Four-and-a-Half LIM Domain Protein 2 Decreases Atherosclerosis in ApoE<sup>-/-</sup> Mice. *Arterioscler Thromb Vasc Biol.* 35(5):1190-7, 2015.
3. BB Patel, A Kasneci, AM Bolt, V Di Lalla, MR Di Iorio, M Raad, **KK Mann** and LE Chalifour. Chronic exposure to bisphenol A reduces successful cardiac remodeling after an experimental myocardial infarction in C57bl/6n mice. *Toxicological Sciences* 146(1):101-15, 2015.
4. \*M Lemaire, LF Negro Silva, CA Lemarié, M Flores-Molina, R Krohn, Smits J, Lehoux S and **KK Mann**. Arsenic exposure increases monocyte adhesion to the vascular endothelium, a pro-atherogenic mechanism. *PlosOne* Sep 2;10(9):e0136592, 2015.
5. RD Morin, SE Assouline, M Alcaide, A Mohajeri, RL Johnston, L Chong, J Grewal, S Yu, D Fornika, K Bushell, T Holm Nielsen, T Petrogiannis-Halioitis, M Crump, A Tosikyan, BM Grande, D Macdonald, C Rousseau, M Bayat, P Sesques, R Froment, M Albuquerque, Y Monczak, K Klein-Oros, C Greenwood, Y Riazalhosseini, M Arseneault, E Camlioglu, AM Constantin, Q Pan-Hammarström, RJ Peng, **KK Mann**, NA Johnson. Genetic landscapes of

relapsed and refractory diffuse large B cell lymphomas. *Clin Cancer Res.* 2015 [Epub ahead of print]

6. M Lemaire and **KK Mann**. Arsenic: Role in Chemotherapy. In: *Arsenic: Exposure Sources, Health Risks and Mechanisms of Toxicity*. Editor: J. Christopher States Publication 2015.

#### **Luke McCaffrey**

1. Halaoui R\*, **McCaffrey L**. Rewiring cell polarity signaling in cancer. *Oncogene*. 2015 Feb 19;34(8):939-50. doi: 10.1038/onc.2014.59. Epub 2014 Mar 17. Review. PubMed PMID: 24632617.
2. Archibald A\*, Mihai C\*, Macara IG, **McCaffrey L**. Oncogenic suppression of apoptosis uncovers a Rac1/JNK proliferation pathway activated by loss of Par3. *Oncogene*. 2015 Jun 11;34(24):3199-206. doi: 10.1038/onc.2014.242. Epub 2014 Aug 11. PubMed PMID: 25109337; PubMed Central PMCID: PMC4324374.
3. Archibald A\*, Al-Masri M\*, Liew-Spilger A\*, **McCaffrey L**. Atypical protein kinase C induces cell transformation by disrupting Hippo/Yap signaling. *Mol Biol Cell*. 2015 Oct 15;26(20):3578-95. doi: 10.1091/mbc.E15-05-0265. Epub 2015 Aug 12. PubMed PMID: 26269582; PubMed Central PMCID: PMC4603929.
4. Carlis Rejon\* and **Luke McCaffrey**. Cell Polarity in Mammary Gland Morphogenesis and Breast Cancer. Ed. K. Ebnet In "Cell Polarity – Volume 2", Springer Press

#### **Christopher McKinnon**

1. **MacKinnon, C. J.**, Smith, N. G., Henry, M., \*Milman, E., Chochinov, H. M., Körner, A., Berish, M., \*Farrace, A., Liarikos, N. & Cohen, S. R. (2015). Reconstructing meaning with others in loss: A feasibility pilot randomized controlled trial of a bereavement group. *Death Studies*, 39 (7), 411-21DOI:10.1080/07481187.2014.958628
2. **MacKinnon, C. J.**, Smith, N. G., Henry, M., \*Milman, E., Berish, M., \*Farrace, A. Körner, A., Chochinov, H. M., & Cohen, S. R. (2015). A pilot study of meaning-based group counseling for bereavement. *Omega: Journal of Death and Dying*. 72 (3), 210-233. DOI: 10.1177/0030222815575002

#### **Ari Meguerditchian**

1. Ramjaun A, Sudarshan M, Patakfalvi L, Tamblyn R, **Meguerditchian AN**. Educating medical trainees on medication reconciliation: a systematic review. *BMC Med Educ*. 2015 Mar 7;15:33. doi: 10.1186/s12909-015-0306-5. Review.

#### **Sarkis Meterissian**

1. Mahdanian AA, Looper KJ, Bacon SL, Mesurole B, **Meterissian SH**, Rej S. Serotonergic antidepressants and increased bleeding risk in patients undergoing breast biopsy. *Ther Adv Psychopharmacol*. 2015 Dec;5(6):332-8. doi: 10.1177/2045125315612014.
2. Parsyan A, Moldoveanu D, Balram B, Wong S, Zhang DD, Svadzian A, Allard-Coutu A, Delisle M, Mesurole B, **Meterissian S**. Influence of preoperative magnetic resonance imaging on the surgical management of breast cancer patients. *Am J Surg*. 2015 Oct 19. pii: S0002 9610(15)00563-2. doi: 10.1016/j.amjsurg.2015.08.028. [Epub ahead of print]
3. Dumitra S, Wong SM, **Meterissian S**, Featherstone R, Barkun J, Fata P. The operative dictation: a review of how this skill is taught and assessed in surgical residency programs. *J Surg Educ*. 2015 Mar-Apr;72(2):321-9. doi: 10.1016/j.jsurg.2014.09.014. Epub 2014 Nov 14.

4. Boileau JF, Poirier B, Basik M, Holloway CM, Gaboury L, Sideris L, **Meterissian S**, Arnaout A, Brackstone M, McCready DR, Karp SE, Trop I, Lisbona A, Wright FC, Younan RJ, Provencher L, Patocskai E, Omeroglu A, Robidoux A. Sentinel node biopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: the SN FNAC study. *J Clin Oncol*. 2015 Jan 20;33(3):258-64. doi: 10.1200/JCO.2014.55.7827.

#### **Catalin Mihalcioiu**

1. Tedeschi AL, Eslami Z, Garoufalis E, Saleh RR, Omeroglu A, Altinel G, Ait-Tihyaty M, Jean-Claude B, **Mihalcioiu C**. Pilot study investigating the prognostic significance of thymidine phosphorylase expression in patients with metastatic breast cancer: a single institution retrospective analysis. *Onco Targets Ther*. 2015 Apr 21;8:911-9. doi: 10.2147/OTT.S71089. eCollection 2015.

#### **Wilson Miller**

1. Aglietta M, Barone C, Sawyer MB, Moore MJ, **Miller WH Jr**, Bagalà C, Colombi F, Cagnazzo C, Gioeni L, Wang E, Huang B, Fly KD, Leone F. A phase I dose escalation trial of tremelimumab (CP-675,206) in combination with gemcitabine in chemotherapy-naïve patients with metastatic pancreatic cancer. *Ann Oncol*. 2014 Sep;25(9):1750-5.
2. Assouline S, Culjkovic-Kraljacic B, Bergeron J, Caplan S, Cocolakis E, Lambert C, Lau CJ, Zahreddine HA, **Miller WH Jr.**, Borden KLB. A Phase I trial of ribavirin and low-dose cytarabine for the treatment of relapsed and refractory acute myeloid leukemia with elevated eIF4E. *Haematologica*,100(1) e7-e9, 2015.
3. Zhan Y, Dahabieh MS, Dobocan MC, Boutchou M-N, Goncalves C, Liu LS, Pettersson F, Rajakumarm A, Topisirovic I, van Kempen L, del Rincón SV, **Miller WH Jr**. The role of eIF4E in response and acquired resistance to vemurafenib in melanoma. *Journal Of Investigative Dermatology*. 135(5):1368-76, 2015.
4. Pettersson F, del Rincon SV, Emond A, Huor B, Ngan E, Ng J, Dobocan MC, Peter Siegel, and **Miller WH Jr**. Genetic and Pharmacologic Inhibition of eIF4E Reduces Breast Cancer Cell Migration, Invasion, and Metastasis. *Cancer Research* 75(6):1102-12, 2015.
5. Hoffer LJ, Robitaille L, Zakarian R, Melnychuk D, Kavan P, Agulnik J, Cohen V, Small D, **Miller WH Jr**. High-Dose Intravenous Vitamin C Combined with Cytotoxic Chemotherapy in Patients with Advanced Cancer: A Phase I-II Clinical Trial. *PLoS One*. 2015 Apr 7;10(4):e0120228. doi: 10.1371/journal.pone.0120228. eCollection 2015.
6. Amin A, Dudek AZ, Logan TF, Lance RS, Holzbeierlein JM, Knox JJ, Master VA, Pal SK, **Miller WH Jr**, Karsh LI, Tcherepanova IY, DeBenedette MA, Williams WL, Plessinger DC, Nicolette CA, Figlin RA. Survival with AGS-003, an autologous dendritic cell-based immunotherapy, in combination with sunitinib in unfavorable risk patients with advanced renal cell carcinoma (RCC): Phase 2 study results. *J Immunother Cancer*. 2015 Apr 21;3:14, 2015.
7. Weber JS, D'Angelo SP, Minor D, Hodi FS, Gutzmer R, Neyns B, Hoeller C, Khushalani NI, **Miller WH Jr**, Lao CD, Linette GP, Thomas L, Lorigan P, Grossmann KF, Hassel JC, Maio M, Sznol M, Ascierto PA, Mohr P, Chmielowski B, Bryce A, Svane IM, Grob JJ, Krackhardt AM, Horak C, Lambert A, Yang AS, Larkin J. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. *Lancet Oncol*. 2015 Apr;16(4):375-84, 2015.

8. Rodon J, Soria JC, Berger R, Batist G, Tsimberidou A, Bresson C, Lee JJ, Rubin E, Onn A, Schilsky RL, **Miller WH Jr**, Eggermont AM, Mendelsohn J, Lazar V, Kurzrock R. Challenges in Initiating and Conducting Personalized Cancer Therapy Trials: Perspectives from WINTHER, a Worldwide Innovative Network (WIN) Consortium Trial. *Annals of Oncol* (2015) doi: 10.1093/annonc/mdv191, 2015.
9. Andtbacka RHI, Kaufman HL, Collichio F, Amatruda T, Senzer N, Chesney J, Delman KA, Spitler L, Puzanov I, Agarwala SS, Milhem M, Cranmer L, Curti B, Lewis K, Ross M, Guthrie T, Linette, GP, Daniels GA, Harrington K, Middleton, MR, **Miller WH Jr.**, Zager J S, Ye Y, Yao B, Li A, Doleman S, VanderWalde A, Gansert J, and Coffin R. Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma. *JCO*. May 26, 2015, doi: 10.1200/JCO.2014.58.3377, 2015.
10. Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, Daud A, Carlino MS, McNeil C, Lotem M, Larkin J, Lorigan P, Neyns B, Blank CU, Hamid O, Mateus C, Shapira-Frommer R, Kosh M, Zhou H, Ibrahim N, Ebbinghaus S, and Ribas A. ;KEYNOTE-006 investigators Carlino MS, Cebon J, Hersey P, Long G, McNeil C, Millward M, Walpole E, Höller C, Kehrer H, Richtig E, Schmuth M, Baurain JF, Neyns B, Wolter P, Butler M, McWhirter E, **Miller WH Jr**, Petrella T, Acevedo A, Caglevic C, Morales L, Sanchez J, Yepes A, Zambrano AR, Avril MF, Dutriaux C, Grob JJ, Guilot B, Lacour JP, Leccia MT, Legoupil D, Lebbe C, Machet L, Mortier L, Robert C, Berking C, Loquai C, Mohr P, Schadendorf D, Utikal J, Bar-Sela G, Lotem M, Schachter J, Blank C, Barrow C, Fitzharris B, Kersten C, Nyakas M, Straume O, Arance A, Berrocal A, Cortes J, Espinosa E, Lopez-Martin J, Martin-Algarra S, Masucci G, Papworth K, Ullenhag G, Brown E, Chao D, Evans T, Larkin J, Lorigan P, Middleton M, Skaria S, Steven N, Agarwala S, Bhatia S, Daud A, Gangadhar T, Gonzalez R, Hamid O, Kumar P, Kuzel T, Lutzky J, O'Day S, Perry D, Pecora A, Puzanov I, Ribas A, Slezak K, Sznol M, Tarhini A, Weiss G. Pembrolizumab versus Ipilimumab in Advanced Melanoma. *N Engl J Med* 372:2521-2532, 2015.

### **Thierry Muanza**

1. Heravi H, Kumala S, Rachid Z, Jean-Claude BJ, Radzioch D, **Muanza T**. ZRBA1, a Mixed EGFR/DNA Targeting Molecule, Potentiates Radiation Response Through Delayed DNA Damage Repair Process in a Triple Negative Breast Cancer Model. *International Journal of Radiation Oncology\*Biophysics\*Physics*. Volume 92(2): 399-406. June 2015
2. Alshami J, Guiot MC, Owen S, Kavan P, Gibson N, Solca F, Sceh A, Reardon DA, **Muanza T**. Afatinib, an irreversible ErbB family blocker, with protracted temozolomide in recurrent glioblastoma: a case report. *Oncotarget* 6(32). DOI: 10.18632/oncotarget.5297. 2015.

### **Alain Nepveu**

1. Pal R, Ramdzan ZM, Kaur S, Duquette PM, Marcotte R, Leduy L, Davoudi S, Lamarche-Vane N, Iulianella A, **Nepveu A**. CUX2 protein functions as an accessory factor in the repair of oxidative DNA damage. *J Biol Chem*. 2015 Sep 11;290(37):22520-31. doi: 10.1074/jbc.M115.651042. Epub 2015 Jul 28.
2. Ramdzan ZM, Pal R, Kaur S, Leduy L, Bérubé G, Davoudi S, Vadnais C, **Nepveu A**. The function of CUX1 in oxidative DNA damage repair is needed to prevent premature senescence of mouse embryo fibroblasts. *Oncotarget*. 2015 Feb 28;6(6):3613-26.

### Scott Owen

1. Alshami J, Guiot MC, **Owen S**, Kavan P, Gibson N, Solca F, Cseh A, Reardon DA, Muanza T. Afatinib, an irreversible ErbB family blocker, with protracted temozolomide in recurrent glioblastoma: a case report. *Oncotarget*. 2015 Oct 20;6(32):34030-7. doi: 10.18632/oncotarget.5297.
2. Azoulay M, Santos F, Souhami L, Panet-Raymond V, Petrecca K, **Owen S**, Guiot MC, Patyka M, Sabri S, Shenouda G, Abdulkarim B. Comparison of radiation regimens in the treatment of Glioblastoma multiforme: results from a single institution. *Radiat Oncol*. 2015 Apr 26;10:106. doi: 10.1186/s13014-015-0396-6.

### Lawrence Panasci

1. McLean J, Rho YS, Kuruba G, Mamo A, Gilabert M, Kavan T, **Panasci L**, Melnychuk D, Batist G, Kavan P. Clinical Practice Patterns in Chemotherapeutic Treatment Regimens for Metastatic Colorectal Cancer. *Clin Colorectal Cancer*. 2015 Oct 21. pii: S1533-0028(15)00118-8.
2. Shen D, Guo CC, Wang J, Qiu ZK, Sai K, Yang QY, Chen YS, Chen FR, Wang J, **Panasci L**, Chen ZP. Interferon- $\alpha/\beta$  enhances temozolomide activity against MGMT-positive glioma stem-like cells. *Oncol Rep*. 2015 Nov;34(5):2715-21.
3. Abu-Sanad A, Wang Y, Hasheminasab F, Panasci J, Noë A, Rosca L, Davidson D, Amrein L, Sharif-Askari B, Aloyz R, **Panasci L**. Simultaneous inhibition of ATR and PARP sensitizes colon cancer cell lines to irinotecan. *Front Pharmacol*. 2015 Jul 22;6:147.

### Morag Park

1. Li J, Davidson D, Martins Souza C, Zhong MC, Wu N, **Park M**, Muller WJ, Veillette A. Loss of PTPN12 Stimulates Progression of ErbB2-Dependent Breast Cancer by Enhancing Cell Survival, Migration, and Epithelial-to-Mesenchymal Transition. *Mol Cell Biol*. 2015 Dec;35(23):4069-82. doi: 10.1128/MCB.00741-15. Epub 2015 Sep 21.
2. Caserta E, Egriboz O, Wang H, Martin C, Koivisto C, Pecót T, Kladney RD, Shen C, Shim KS, Pham T, Karikomi MK, Mauntel MJ, Majumder S, Cuitino MC, Tang X, Srivastava A, Yu L, Wallace J, Mo X, **Park M**, Fernandez SA, Pilarski R, La Perle KM, Rosol TJ, Coppola V, Castrillon DH, Timmers C, Cohn DE, O'Malley DM, Backes F, Suarez AA, Goodfellow P, Chamberlin HM, Macrae ER, Shapiro CL, Ostrowski MC, Leone G. Noncatalytic PTEN missense mutation predisposes to organ-selective cancer development in vivo. *Genes Dev*. 2015 Aug 15;29(16):1707-20. doi: 10.1101/gad.262568.115.
3. Oh EY, Christensen SM, Ghanta S, Jeong JC, Bucur O, Glass B, Montaser-Kouhsari L, Knoblauch NW, Bertos N, Saleh SM, Haibe-Kains B, **Park M**, Beck AH. Extensive rewiring of epithelial-stromal co-expression networks in breast cancer. *Genome Biol*. 2015 Jun 19;16:128. doi: 10.1186/s13059-015-0675-4.
4. Mui MZ, Zhou Y, Blanchette P, Chughtai N, Knight JF, Gruosso T, Papadakis AI, Huang S, **Park M**, Gingras AC, Branton PE. The Human Adenovirus Type 5 E4orf4 Protein Targets Two Phosphatase Regulators of the Hippo Signaling Pathway. *J Virol*. 2015 Sep;89(17):8855-70. doi: 10.1128/JVI.03710-14. Epub 2015 Jun 17.
5. Li R, Knight JF, **Park M**, Pendergast AM. Abl Kinases Regulate HGF/Met Signaling Required for Epithelial Cell Scattering, Tubulogenesis and Motility. *PLoS One*. 2015 May 6;10(5):e0124960. doi: 10.1371/journal.pone.0124960. eCollection 2015.

6. Tabariès S, Annis MG, Hsu BE, Tam CE, Savage P, **Park M**, Siegel PM. Lyn modulates Claudin-2 expression and is a therapeutic target for breast cancer liver metastasis. *Oncotarget*. 2015 Apr 20;6(11):9476-87.
7. You L, Yan K, Zou J, Zhao H, Bertos NR, **Park M**, Wang E, Yang XJ. The chromatin regulator Brpf1 regulates embryo development and cell proliferation. *J Biol Chem*. 2015 May 1;290(18):11349-64. doi: 10.1074/jbc.M115.643189. Epub 2015 Mar 15.
8. You L, Yan K, Zou J, Zhao H, Bertos NR, **Park M**, Wang E, Yang XJ. The lysine acetyltransferase activator Brpf1 governs dentate gyrus development through neural stem cells and progenitors. *PLoS Genet*. 2015 Mar 10;11(3):e1005034. doi: 10.1371/journal.pgen.1005034. eCollection 2015 Mar. Erratum in: *PLoS Genet*. 2015 Jun;11(6):e1005329. Zhou, Jinfeng [corrected to Zou, Jinfeng].
9. Ioannou MS, Bell ES, Girard M, Chaineau M, Hamlin JN, Daubaras M, Monast A, **Park M**, Hodgson L, McPherson PS. DENND2B activates Rab13 at the leading edge of migrating cells and promotes metastatic behavior. *J Cell Biol*. 2015 Mar 2;208(5):629-48. doi: 10.1083/jcb.201407068. Epub 2015 Feb 23.
10. You L, Zou J, Zhao H, Bertos NR, **Park M**, Wang E, Yang XJ. Deficiency of the chromatin regulator BRPF1 causes abnormal brain development. *J Biol Chem*. 2015 Mar 13;290(11):7114-29. doi: 10.1074/jbc.M114.635250. Epub 2015 Jan 7.

#### **William Parker**

1. Toltz A, Shin N, Mitrou E, Laude C, Freeman CR, Seuntjens J, **Parker W**, Roberge D. Late radiation toxicity in Hodgkin lymphoma patients: proton therapy's potential. *J Appl Clin Med Phys*. 2015 Sep 8;16(5):5386.
2. Videtic GM, Hu C, Singh AK, Chang JY, **Parker W**, Olivier KR, Schild SE, Komaki R, Urbanic JJ, Choy H. A Randomized Phase 2 Study Comparing 2 Stereotactic Body Radiation Therapy Schedules for Medically Inoperable Patients With Stage I Peripheral Non-Small Cell Lung Cancer: NRG Oncology RTOG 0915 (NCCTG N0927). *Int J Radiat Oncol Biol Phys*. 2015 Nov 15;93(4):757-64. doi: 10.1016/j.ijrobp.2015.07.2260. Epub 2015 Jul 17.

#### **Jerry Pelletier**

1. Malina A, Cameron CJ, Robert F, Blanchette M, Dostie J, **Pelletier J**. PAM multiplicity marks genomic target sites as inhibitory to CRISPR-Cas9 editing. *Nat Commun*. 2015 Dec 8;6:10124. doi: 10.1038/ncomms10124.
2. Chu J, Cencic R, Wang W, Porco JA Jr, **Pelletier J**. Translation Inhibition by Rocaglates Is Independent of eIF4E Phosphorylation Status. *Mol Cancer Ther*. 2016 Jan;15(1):136-41. doi: 10.1158/1535-7163.MCT-15-0409. Epub 2015 Nov 19.
3. Cencic R, Senechal P, **Pelletier J**. Establishment of a Primary Screening Assay for the DHX9 Helicase. *Comb Chem High Throughput Screen*. 2015;18(9):855-61.
4. Robert F, Barbeau M, Éthier S, Dostie J, **Pelletier J**. Pharmacological inhibition of DNA-PK stimulates Cas9-mediated genome editing. *Genome Med*. 2015 Aug 27;7(1):93. doi: 10.1186/s13073-015-0215-6.
5. Galicia-Vázquez G, Chu J, **Pelletier J**. eIF4AII is dispensable for miRNA-mediated gene silencing. *RNA*. 2015 Oct;21(10):1826-33. doi: 10.1261/rna.052225.115. Epub 2015 Aug 18.
6. Obatoclax is a direct and potent antagonist of membrane-restricted Mcl-1 and is synthetic lethal with treatment that induces Bim. Nguyen M, Cencic R, Ertel F, Bernier C, **Pelletier J**,

- Roulston A, Silvius JR, Shore GC. *BMC Cancer*. 2015 Aug 1;15:568. doi: 10.1186/s12885-015-1582-5.
- González-Almela E, Sanz MA, García-Moreno M, Northcote P, **Pelletier J**, Carrasco L. Differential action of pateamine A on translation of genomic and subgenomic mRNAs from Sindbis virus. *Virology*. 2015 Oct;484:41-50. doi: 10.1016/j.virol.2015.05.002. Epub 2015 Jun 5.
  - Andrei AZ, Hall A, Smith AL, Bascuñana C, Malina A, Connor A, Altinel-Omeroglu G, Huang S, **Pelletier J**, Huntsman D, Gallinger S, Omeroglu A, Metrakos P, Zogopoulos G. Increased in vitro and in vivo sensitivity of BRCA2-associated pancreatic cancer to the poly(ADP-ribose) polymerase-1/2 inhibitor BMN 673. *Cancer Lett*. 2015 Aug 1;364(1):8-16. doi: 10.1016/j.canlet.2015.04.003. Epub 2015 Apr 9.
  - Methot SP, Litzler LC, Trajtenberg F, Zahn A, Robert F, **Pelletier J**, Buschiazzo A, Magor BG, Di Noia JM. Consecutive interactions with HSP90 and eEF1A underlie a functional maturation and storage pathway of AID in the cytoplasm. *J Exp Med*. 2015 Apr 6;212(4):581-96. doi: 10.1084/jem.20141157. Epub 2015 Mar 30.
  - Bhat M, Robichaud N, Hulea L, Sonenberg N, **Pelletier J**, Topisirovic I. Targeting the translation machinery in cancer. *Nat Rev Drug Discov*. 2015 Apr;14(4):261-78. doi: 10.1038/nrd4505. Epub 2015 Mar 6. Review.
  - Blagih J, Coulombe F, Vincent EE, Dupuy F, Galicia-Vázquez G, Yurchenko E, Raissi TC, van der Windt GJ, Viollet B, Pearce EL, **Pelletier J**, Piccirillo CA, Krawczyk CM, Divangahi M, Jones RG. The energy sensor AMPK regulates T cell metabolic adaptation and effector responses in vivo. *Immunity*. 2015 Jan 20;42(1):41-54. doi: 10.1016/j.immuni.2014.12.030. Epub 2015 Jan 2.
  - Pelletier J**, Graff J, Ruggero D, Sonenberg N. Targeting the eIF4F translation initiation complex: a critical nexus for cancer development. *Cancer Res*. 2015 Jan 15;75(2):250-63. doi: 10.1158/0008-5472.CAN-14-2789. Review.
  - Malina A, Katigbak A, Cencic R, Maïga RI, Robert F, Miura H, **Pelletier J**. Adapting CRISPR/Cas9 for functional genomics screens. *Methods Enzymol*. 2014;546:193-213. doi: 10.1016/B978-0-12-801185-0.00010-6.
  - Chu J, **Pelletier J**. Targeting the eIF4A RNA helicase as an anti-neoplastic approach. *Biochim Biophys Acta*. 2015 Jul;1849(7):781-91. doi: 10.1016/j.bbagr.2014.09.006. Epub 2014 Sep 16. Review.

#### **Alan Peterson**

- Dionne N, Dib S, Finsen B, Denarier E, Kuhlmann T, Drouin R, Kokoeva M, Hudson TJ, Siminovitch K, Friedman HC, **Peterson AC**. Functional organization of an Mbp enhancer exposes striking transcriptional regulatory diversity within myelinating glia. *Glia*. 2016 Jan;64(1):175-94. doi: 10.1002/glia.22923. Epub 2015 Oct 28. PMID:26507463

#### **Michael Pollak**

- \*Assayag J, **Pollak MN**, Azoulay L. The Use of Aspirin and the Risk of Mortality in Patients with Prostate Cancer. *J Urol* 193: 1220-5, 2015.
- Blouin MJ, Bazile M, Birman E, Zakikhani M, Florianova L, Aleynikova O, Powell DR, **Pollak M**. Germ line knockout of IGF1R-3 reveals influences of the gene on mammary gland neoplasia. *Breast Cancer Res Treat* 149: 577-85, 2015.



**Department of Oncology Annual Report 2015**  
**Publications**

3. \*Morita M, Gravel SP, Hulea L, Larsson O, **Pollak M**, St-Pierre J, Topisirovic I. mTOR coordinates protein synthesis, mitochondrial activity and proliferation. *Cell Cycle* 14: 473-80, 2015.
4. Cifarelli V, Lashinger LM, Devlin KL, Dunlap SM, Huang J, Kaaks R, Pollak MN, Hursting SD. Metformin and rapamycin reduce pancreatic cancer \*Assayag J, **Pollak MN**, Azoulay L. The Use of Aspirin and the Risk of Mortality in Patients with Prostate Cancer. *J Urol* 193: 1220-5, 2015.
5. Blouin MJ, Bazile M, Birman E, Zakikhani M, Florianova L, Aleynikova O, Powell DR, **Pollak M**. Germ line knockout of IGFBP-3 reveals influences of the gene on mammary gland neoplasia. *Breast Cancer Res Treat* 149: 577-85, 2015.
6. \*Morita M, Gravel SP, Hulea L, Larsson O, **Pollak M**, St-Pierre J, Topisirovic I. mTOR coordinates protein synthesis, mitochondrial activity and proliferation. *Cell Cycle* 14: 473-80, 2015.
7. Cifarelli V, Lashinger LM, Devlin KL, Dunlap SM, Huang J, Kaaks R, **Pollak MN**, Hursting SD. Metformin and rapamycin reduce pancreatic cancer and Risk of Endometriosis. *Am J Epidemiol* 182: 148-56, 2015.
8. Catsburg C, Gunter MJ, Tinker L, Chlebowski RT, **Pollak M**, Strickler HD, Cote ML, Page DL, Rohan TE. Serum IGFBP-2 and Risk of Atypical Hyperplasia of the Breast. *J Cancer Epidemiol* 2015, 2015.
9. Houghton LC, **Pollak MN**, Tao Y, Tu YG, Black A, Bradwin G, Hoover RN, Troisi R. Similarity of Serum and Plasma Insulin-like Growth Factor Concentrations. *Biomark Cancer*. 2015 Jun 8: eCollection 2015.
10. Stolzenberg-Solomon RZ, Newton CC, Silverman DT, **Pollak M**, Nogueira LM, Weinstein SJ, Albanes D, Männistö S, Jacobs EJ. Circulating Leptin and Risk of Pancreatic Cancer: A Pooled Analysis From 3 Cohorts. *Am J Epidemiol* 182: 187-97, 2015
11. Azoulay L, Eberg M, Benayoun S, **Pollak M**. 5 $\alpha$ -Reductase Inhibitors and the Risk of Cancer-Related Mortality in Men With Prostate Cancer. *JAMA Oncol* 1: 314-20, 2015.
12. Chapman JW, Costantino JP, Dong B, Margolese RG, Pritchard KI, Shepherd LE, Gelmon KA, Wolmark N, **Pollak MN**. Octreotide LAR and tamoxifen versus tamoxifen in phase III randomize early breast cancer trials: NCIC CTG MA.14 and NSABP B-29. *Breast Cancer Res and Treat* 153: 353-60, 2015.
13. Inamura K, Song M, Jung S, Nishihara R, Yamauchi M, Lochhead P, Qian ZR, Kim SA, Mima K, Sukawa Y, Masuda A, Imamura Y, Zhang X, **Pollak MN**, Mantzoros CS, Harris CC, Giovannucci E, Fuchs CS, Cho E, Chan AT, Wu K, Ogino S. Prediagnosis Plasma Adiponectin in Relation to Colorectal Cancer Risk According to KRAS Mutation Status. *J Natl Cancer Inst* 108, 2015.
14. Allen DB, Backeljauw P, Bidlingmaier M, Biller B, Boguszewski M, Burman P, Butler G, Chihara K, Christiansen JS, Cianfarani S, Clayton PE, Clemmons D, Cohen P, Darendeliler F, Deal C, Dunger DP, Erfurth EM, Fuqua J, Grimberg A, Haymond M, Higham C, Ho KK, Hoffman AR, Hokken-Koelega AC, Johannsson G, Juul A, Kopchick JJ, Lee P, **Pollak M**, Radovick S, Robison L, Rosenfeld R, Ross RJ, Savendahl L, Saenger P, Toft Sorensen H, Stochholm K, Strasburger CJ, Swerdlow A, Thorner MO. Growth Hormone Safety Workshop Position Paper: a critical appraisal of recombinant human growth hormone therapy in children and adults. *Eur J Endocrinol*. 2015 Nov 12. Epub ahead of print.

### Raghu Rajan

1. Rosenthal SA; Hunt D; Sartor AO; Pienta KJ; Gomella L; Grignon D; **Rajan R**; Kerlin KJ; Jones CU; Dobelbower M; Shipley WU; Zeitzer K; Hamstra DA; Donavanik V; Rotman M; Hartford AC; Michalski J; Seider M; Kim H; Kuban DA; Moughan J; Sandler H. A Phase 3 Trial of 2 Years of Androgen Suppression and Radiation Therapy With or Without Adjuvant Chemotherapy for High-Risk Prostate Cancer: Final Results of Radiation Therapy Oncology Group Phase 3 Randomized Trial NRG Oncology RTOG 9902. *International Journal of Radiation Oncology, Biology, Physics*. 93(2):294-302, 2015 Oct 1.
2. Boily G, Filion E, Rakovich G, Kopek N, Tremblay L, Samson B, Goulet S, Roy I and **the Comité de l'évolution des pratiques en oncologie** (CEPO). Stereotactic ablative radiation therapy for the treatment of non-small cell lung cancer: CEPO review and recommendations. *J Thorac Oncol* 2015;10(6):872-82.
3. Boulanger J, Ducharme A, Dufour A, Fortier S, Almanric K and a collaboration of **the Comité de l'évolution de la pratique des soins pharmaceutiques** (CEPSP) and the Comité de l'évolution des pratiques en oncologie (CEPO). Management of the extravasation of antineoplastic agents. *Supportive care in cancer* 2015; 23(5):1459-71.

### Stéphane Richard

1. Song J. and **S. Richard**. 2015. Sam68 regulates S6K1 alternative splicing during adipogenesis. *Molecular Cellular Biology* 35:1926-39
2. Gurunathan, G., Z. Yu, Y. Coulombe, J.-Y. Masson, and **S. Richard**. 2015. Arginine methylation of hnRNPUL1 regulates interaction with NBS1 and recruitment to sites of DNA damage. *Scientific Reports* 5: 10475doi: 10.1038/srep10475.
3. Zhou, J., M. Cheng, C. Boriboun, M.M. Ardehali, C. Jiang, Q. Liu, S. Han, D. A. Goukassian, Y.L. Tang, T. Zhao, M. Zhao, L. Cai, **S. Richard**, R. Kishore, and G.Qin. 2015. Inhibition of Sam68 triggers adipose tissue browning. *J Endo* 225:181-9
4. Thandapani, P.J. Song, V. Gandin, Y. Cai, S. G. Rouleau, J.-M. Garant, F.-M. Boisvert, Z. Yu, J.-P. Perreault, I. Topisirovic, and **S. Richard**. 2015. Aven recognition of RNA G-quadruplexes regulates translation of the mixed lineage leukemia protooncogenes. *eLife* 2015;10.7554/eLife.06234
5. Calibretta, S and **S. Richard**. 2015. Emerging roles of disordered sequences in RNA-binding proteins. *Trends Biochem Sci* 40:662-72
6. Haines JD, D.L Fulton, **S. Richard** and G. Almazan. 2015. P38 mitogen-activated protein kinase pathway regulates genes during proliferation and differentiation in oligodendrocytes. *PLoS One* e0145843.

### Zeev Rosberger

1. Henry M, Bdira A, Cherba M, Lambert S, Carnevale FA, MacDonald C, Hier M, Zeitouni A, Kost K, Mlynarek A, Black M, **Rosberger Z**, Frenkiel S. Recovering function and surviving treatments are primary motivators for health behavior change in patients with head and neck cancer: Qualitative focus group study. *Palliat Support Care*. 2015 Nov 23:1-12. [Epub ahead of print]
2. **Rosberger Z**, Perez S, Bloom J, Shapiro GK, Fielding R. The missing piece: cancer prevention within psycho-oncology - a commentary. *Psychooncology*. 2015 Sep 10. doi: 10.1002/pon.3916. [Epub ahead of print]

3. Perez S, Shapiro GK, Brown CA, Dube E, Ogilvie G, **Rosberger Z**. 'I didn't even know boys could get the vaccine': Parents' reasons for human papillomavirus (HPV) vaccination decision making for their sons. *Psychooncology*. 2015 Jul 7. doi: 10.1002/pon.3894. [Epub ahead of print]
4. Krawczyk A, Perez S, King L, Vivion M, Dubé E, **Rosberger Z**. Parents' decision-making about the human papillomavirus vaccine for their daughters: II. Qualitative results. *Hum Vaccin Immunother*. 2015;11(2):330-6. doi: 10.4161/21645515.2014.980708.
5. Krawczyk A, Knäuper B, Gilca V, Dubé E, Perez S, Joyal-Desmarais K, **Rosberger Z**. Parents' decision-making about the human papillomavirus vaccine for their daughters: I. Quantitative results. *Hum Vaccin Immunother*. 2015;11(2):322-9. doi: 10.1080/21645515.2014.1004030.

#### **Siham Sabri**

1. Karen Jung, **Siham Sabri\***, John Hanson, Yaoxian Xu, Ying Wayne Wang, Raymond Lai, and Bassam Abdulkarim\*. Elevated ARG1 expression in primary monocytes-derived macrophages as a predictor of radiation-induced acute skin toxicities in early breast cancer patients. *Cancer Biol Ther*. 2015 Jun 10:0. [Epub ahead of print]
2. Melissa Azoulay, Fabiano Santos, Luis Souhami, Valerie Panet-Raymond, Kevin Petrecca, Scott Owen, Marie-Christine Guiot, Maria Patyka, **Siham Sabri**, George Shenouda, Bassam Abdulkarim. Comparison of Radiation Regimens in the Treatment of Glioblastoma Multiforme: Results from a Single Institution. *Radiat Oncol*. 2015 Apr 26;10(1):106.

#### **Jan Seuntjens**

1. M.A. Renaud, D. Roberge, **J. Seuntjens** (2015) Latent uncertainties of the pre-calculated track Monte Carlo method, *Medical Physics* 42(1): 479.
2. Asgharizadeh S, Bekerat H, Syme A, Aldelaijan S, DeBlois F, Vuong T, Evans M, **Seuntjens J**, Devic S (2015) Radiochromic film-based quality assurance for CT-based high-dose-rate brachytherapy, *Brachytherapy* 14(4):578-585 (July-August 2015).
3. Lee S, Ybarra N, Jeyaseelan K, Faria S, Kopek N, Brisebois P, Bradley JD, Robinson C, **Seuntjens J**, El Naqa I. (2015) Bayesian network ensemble as a multivariate strategy to predict radiation pneumonitis risk, *Med Phys* 42(5): 2421.
4. H. Bouchard, Y. Kamio, H. Palmans, **J. Seuntjens**, S. Duane, (2015) Detector dose response in megavoltage small photon beams. II. Pencil beam perturbation effects, *Med. Phys.* 42(10):6048-6061.
5. H. Bouchard, **J. Seuntjens**, S. Duane, Y. Kamio, H. Palmans (2015) Detector dose response in megavoltage small photon beams. I. Theoretical concepts, *Med. Phys.* 42(10):6033-6047.
6. R. Maglieri, A. Licea, Me. Evans, **J. Seuntjens**, J. Kildea (2015) Measuring neutron spectra in radiotherapy using the nested neutron spectrometer, *Med. Phys.* 42(11):6162-6169.
7. Beaulieu L, Naqa IE, Després P, **Seuntjens J**. (2015) Special section: Selected papers from the Fifth International Workshop on Monte Carlo Techniques in Medical Physics, *Phys Med Biol*. 60(13):4947-4950.
8. Ola M Maria, Ahmed M Maria, Norma Ybarra, Krishinima Jeyaseelan, Sangkyu Lee, Jessica Perez, Mostafa Y Shalaby, Shirley Lehnert, Sergio Faria, Monica Serban, **Jan Seuntjens**, Issam El Naqa Mesenchymal Stem Cells Adopt Lung Cell Phenotype in Normal and Radiation-induced Lung Injury Conditions, *Applied immunohistochemistry & molecular morphology*: (July 2015, in press) doi: 10.1097/PAI.0000000000000180

9. PG Watson, E Mainegra-Hing, N Tomic, **J Seuntjens**. (2015) Implementation of an efficient Monte Carlo calculation for CBCT scatter correction: phantom study, *Journal of Applied Clinical Medical Physics* 16(4): 5393.
10. D. Roberge, C. Leclerc-Champagne, R. Doucet and **J. Seuntjens** (2015) How Low Should You Go: Choice of Minimum Dose Prescription in Cranial Radiosurgery, *Cureus, Journal of Medical Science* 7(6): e282.
11. Renaud J, Sarfehnia A, Marchant K, McEwen M R, Ross C, **Seuntjens J P** (2015) Direct measurement of electron beam quality conversion factors using water calorimetry, *Med. Phys.* 42(11), 6357-6368.
12. A Toltz †, N Shin, E. Mitrou, C Laude, C Freeman, **J Seuntjens**, W Parker, D Roberge (2015) Late radiation toxicity in Hodgkin lymphoma patients; proton therapy's potential, *Journal of Applied Clinical Medical Physics* 16(5).[http://jacmp.org/index.php/jacmp/article/view/5386/html\\_354](http://jacmp.org/index.php/jacmp/article/view/5386/html_354) .
13. D. Fang, S. Hu, Y. Liu, V-H Quan, **J. Seuntjens** & S. D. Tran (2015) Identification of the active components in Bone Marrow Soup: a mitigator against irradiation-injury to salivary glands, *Scientific Reports* 5:16017, Nov. 2015 Published.

### **George Shenouda**

1. Al-Wassia R, Vakilian S, Holly C, Sultanem K, **Shenouda G**. A retrospective study of head and neck re-irradiation for patients with recurrent or second primary head and neck cancer: the McGill University experience. *J Otolaryngol Head Neck Surg.* 2015 Sep 2;44:31. doi: 10.1186/s40463-015-0084-4.
2. Azoulay M, Santos F, Souhami L, Panet-Raymond V, Petrecca K, Owen S, Guiot MC, Patyka M, Sabri S, **Shenouda G**, Abdulkarim B. Comparison of radiation regimens in the treatment of Glioblastoma multiforme: results from a single institution. *Radiat Oncol.* 2015 Apr 26;10:106. doi: 10.1186/s13014-015-0396-6.
3. **Shenouda G**, Zhang Q, Ang KK, Machtay M, Parliament MB, Hershock D, Suntharalingam M, Lin A, Rotman M, Nabid A, Hong S, Shehata S, Cmelak AJ, Sultanem K, Le QT. Long-term results of radiation therapy oncology group 9903: a randomized phase 3 trial to assess the effect of erythropoietin on local-regional control in anemic patients treated with radiation therapy for squamous cell carcinoma of the head and neck. *Int J Radiat Oncol Biol Phys.* 2015 Apr 1;91(5):907-15. doi: 10.1016/j.ijrobp.2014.12.018. Epub 2015 Feb 7.
4. Whelan TJ, Olivetto IA, Parulekar WR, Ackerman I, Chua BH, Nabid A, Vallis KA, White JR, Rousseau P, Fortin A, Pierce LJ, Manchul L, Chafe S, Nolan MC, Craighead P, Bowen J, McCready DR, Pritchard KI, Gelmon K, Murray Y, Chapman JA, Chen BE, Levine MN; **MA.20 Study Investigators**. Regional Nodal Irradiation in Early-Stage Breast Cancer. *N Engl J Med.* 2015 Jul 23;373(4):307-16. doi: 10.1056/NEJMoa1415340.

### **Luis Souhami**

1. \*Barbosa Neto O, **Souhami L**, Faria S. Hypofractionated radiation therapy for prostate cancer: The McGill University Health Center experience. *Cancer Radiother.* 2015 Oct;19(6-7):431-6.
2. Warner A, Pickles T, Crook J, Martin AG, **Souhami L**, Catton C, Lukka H, Rodrigues G. Development of ProCaRS Clinical Nomograms for Biochemical Failure-free Survival Following Either Low-Dose Rate Brachytherapy or Conventionally Fractionated External Beam Radiation Therapy for Localized Prostate Cancer. *Cureus.* 2015 Jun 11;7(6):e276.

3. \*Lecavalier-Barsoum M, **Souhami L**, Cury F, Duclos M, Ruo R, Faria S. Pelvic lymph node displacement in high-risk prostate cancer patients treated with image guided intensity modulated radiation therapy with 2 independent target volumes. *Pract Radiat Oncol*. 2015 Nov-Dec;5(6):406-10.
4. Krauss DJ, Hu C, Bahary JP, **Souhami L**, Gore EM, Chafe SM, Leibenhaut MH, Narayan S, Torres-Roca J, Michalski J, Zeitzer KL, Donavanik V, Sandler H, McGowan DG, Jones CU, Shipley WU. Importance of Local Control in Early-Stage Prostate Cancer: Outcomes of Patients With Positive Post-Radiation Therapy Biopsy Results Treated in RTOG 9408. *Int J Radiat Oncol Biol Phys*. 2015 Jul 15;92(4):863-73
5. Vogelbaum MA, Hu C, Peereboom DM, Macdonald DR, Giannini C, Suh JH, Jenkins RB, Laack NN, Brachman DG, Shrieve DC, **Souhami L**, Mehta MP. Phase II trial of pre-irradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligoastrocytomas: long term results of RTOG BR0131. *J Neurooncol*. 2015 Sep;124(3):413-20.
6. \*Azoulay M, Santos F, **Souhami L**, Panet-Raymond V, Petrecca K, Owen S, Guiot MC, Patyka M, Sabri S, Shenouda G, Abdulkarim B. Comparison of radiation regimens in the treatment of Glioblastoma multiforme: results from a single institution. *Radiat Oncol*. 2015 Apr 26;10:106.
7. Viswanathan AN, Moughan J, Miller BE, Xiao Y, Jhingran A, Portelance L, Bosch WR, Matulonis UA, Horowitz NS, Mannel RS, **Souhami L**, Erickson BA, Winter KA, Small W Jr, Gaffney DK. NRG Oncology/RTOG 0921: A phase 2 study of postoperative intensity-modulated radiotherapy with concurrent cisplatin and bevacizumab followed by carboplatin and paclitaxel for patients with endometrial cancer. *Cancer*. 2015 Apr 6. doi: 10.1002/cncr.29337. [Epub ahead of print]
8. Coates J, Jeyaseelan AK, Ybarra N, David M, Faria S, **Souhami L**, Cury F, Duclos M, El Naqa I. Contrasting analytical and data-driven frameworks for radiogenomic modeling of normal tissue toxicities in prostate cancer. *Radiother Oncol*. 2015 Apr;115(1):107-13.
9. Faria S, Cury F, **Souhami L**. Prospective phase I study on testicular castration induced by radiation treatment. *Can J Urol*. 2015 Feb;22(1):7635-9.
10. Mason MD, Parulekar WR, Sydes MR, Brundage M, Kirkbride P, Gospodarowicz M, Cowan R, Kostashuk EC, Anderson J, Swanson G, Parmar MK, Hayter C, Jovic G, Hiltz A, Hetherington J, Sathya J, Barber JB, McKenzie M, El-Sharkawi S, **Souhami L**, Hardman PD, Chen BE, Warde P. Final Report of the Intergroup Randomized Study of Combined Androgen-Deprivation Therapy Plus Radiotherapy Versus Androgen-Deprivation Therapy Alone in Locally Advanced Prostate Cancer. *J Clin Oncol*. 2015 Jul 1;33(19):2143-50.
11. Roberge D, **Souhami L**. High-grade gliomas. In: Principles and Practice of Stereotactic Radiosurgery. Chin LS, Regine WF (eds). Springer Science, (2nd Edition) pp:249-267, 2015.
12. Loureiro LVM, Malheiros SMF, **Souhami L**. Central Nervous System Tumors. In Tropical Hemato-Oncology. Droz J-P, Carme B, Croupiie P, Nacher M, Thieblemont C (eds). Spring Chan, Heidelberg, New York, Dordrecht, London. Pp: 457-463, 2015.

### Barry Stein

1. Lee L, Mata J, Ghitulescu GA, Boutros M, Charlebois P, **Stein B**, Liberman AS, Fried GM, Morin N, Carli F, Latimer E, Feldman LS. Cost-effectiveness of Enhanced Recovery Versus Conventional Perioperative Management for Colorectal Surgery. *Ann Surg*. 2015 Dec;262(6):1026-33. doi: 10.1097/SLA.0000000000001019.

### **Gabriela Stroian**

1. Rabinovich A, Bernard L, Ramanakumar AV, **Gabriela Stroian**, Gotlieb WH, Lau S, Boris Bahoric. Para-aortic and pelvic extended-field radiotherapy for advanced-stage uterine cancer: dosimetric and toxicity comparison between the four-field box and intensity-modulated techniques. *Current Oncology* December 31, 2015

### **Jeremy Sturgeon**

1. Srikanthan A, Tran B, Beausoleil M, Jewett MA, Hamilton RJ, **Sturgeon JF**, O'Malley M, Anson-Cartwright L, Chung PW, Warde PR, Winkquist E, Moore MJ, Amir E, Bedard PL. Large retroperitoneal lymphadenopathy as a predictor of venous thromboembolism in patients with disseminated germ cell tumors treated with chemotherapy. *J Clin Oncol*. 2015 Feb 20;33(6):582-7. doi: 10.1200/JCO.2014.58.6537. Epub 2015 Jan 20.

### **Khalil Sultanem**

1. Shenouda G, Zhang Q, Ang K, Machtay M, Parliament MB, Hershock D, Suntharalingam M, Lin A, Rotman M, Nabid A, Hong S, Shehata S, Cmelak AJ, **Sultanem K**, Le Q-T. Long-Term Results of Radiation Therapy Oncology Group 9903: A Randomized Phase 3 Trial to Assess the Effect of Erythropoietin on Local-Regional Control in Anemic Patients Treated With Radiation Therapy for Squamous Cell Carcinoma of the Head and Neck. *Radiation Oncology Biology Physics*. Volume 91(5): 907-915. April 2015.
2. Wong RKW, Deshmukh S, Wyatt G, Sagar S, Singh A, **Sultanem K**, Nguyen-Tan PF, Yom SS, Cardinale J, Yao M, Hodson I, Matthiesen CL, Suh J, Thakrar H, Pugh SL, Berk L. Acupuncture-Like Transcutaneous Electrical Nerve Stimulation Versus Pilocarpine in Treating Radiation-Induced Xerostomia: Results of RTOG 0537 Phase 3 Study. *Radiation Oncology Biology Physics*. Volume 92(2): 220-227. June 2015

### **Ivan Topisirovic**

1. Takizawa I, Lawrence MG, Balanathan P, Rebello R, Pearson HB, Garg E, Pedersen J, Pouliot N, Nadon R, Watt MJ, Taylor RA, Humbert P, **Topisirovic I**, Larsson O, Risbridger GP, Furic L. Estrogen receptor alpha drives proliferation in PTEN-deficient prostate carcinoma by stimulating survival signaling, MYC expression and altering glucose sensitivity. *Oncotarget*. 2015 Jan 20;6(2):604-16
2. Morita M\*, Gravel SP\*, Hulea L\*, Larsson O, Pollak M, St-Pierre J\*\*, **Topisirovic I\*\***. (2015) mTOR coordinates protein synthesis, mitochondrial activity and proliferation. *Cell Cycle* 14(4):473-80. PMID:25590164 (\*equally contributing authors; \*\*co-corresponding authors).
3. Zhan Y, Dahabieh MS, Rajakumar A, Dobocan MC, M'Boutchou MN, Goncalves C, Shiru L, Pettersson F, **Topisirovic I**, van Kempen L, Del Rincón SV, Miller Jr WH. The Role of eIF4E in Response and Acquired Resistance to Vemurafenib in Melanoma. (2015) *J Invest Dermatol*. 2015 Jan 23. doi: 10.1038/jid.2015.11. [Epub ahead of print]
4. Bhat M\*, Robichaud N\*, Hulea L\*, Sonenberg N\*\*, Pelletier J\*\*, **Topisirovic I\*\*** (2015) Targeting translational machinery in cancer *Nature Reviews|Drug Discovery* (\*equally contributing authors; \*\*co-corresponding authors). Apr;14(4):261-78. doi: 10.1038/nrd4505.
5. **Topisirovic I\*\***, Sonenberg N\*\* Translation and cancer. (2015) *Biochim Biophys Acta*. pii: S1874-9399(15)00102-9. doi: 10.1016/j.bbagr.2015.05.004. (\*\*co-corresponding authors).

6. Thandapani P, Song J, Gandin V, Cai Y, Rouleau SG, Garant JM, Boisvert FM, Yu Z, Perreault JP, **Topisirovic I**, Richard S (2015). Aven recognition of RNA G-quadruplexes regulates translation of the mixed lineage leukemia protooncogenes. *Elife*. doi: 10.7554/eLife.06234.
7. Feng Y, Pinkerton AB, Hulea L, Zhang T, Cheli Y, Davies MA, Yin H, Lau E, Kim H, Barile E, De SK, Pellicchia M, Bosenberg MW, Li JL, James B, Brown KM, **Topisirovic I**, Ronai ZA (2015) Targeting drug resistant and clinically unresponsive subtypes of melanomas using newly developed inhibitor of eIF4F *Cancer Res.* 75(24):5211-8.
8. Furic L, Beardsley E, **Topisirovic I** (2015) The Role of eIF4E Phosphorylation Downstream of MAPK Pathway in Cancer Biology. In “Translation and Its Regulation in Cancer Biology and Medicine” Parsyan A (Ed.) Springer ISBN 978-94-017-9077-2.
9. Gandin V, **Topisirovic I**, Masahiro Morita. (2015) “Translational Control and Translatome in Cancer” *Cell Technology*, 34,756-761

#### **Anna Towers**

1. Belanger E, Tetrault D, Tradounsky G, **Towers A**, Marchessault J, Accuracy and Usefulness of the Palliative Prognostic Index when Administered by a Nurse in a Community Setting, *International Journal of Palliative Nursing*, 2015 Dec 2;21(12):602-605
2. Thomas R, Hack T, Quinlan E, Tatemichi S, **Towers A**, Kwan W, Miedema B, Tilley A, Hamoline R, Morrison T. Loss, adaptation and new directions: the impact of arm morbidity on leisure activities following breast cancer, *Canadian Oncology Nursing Journal* 2015, 25(1): 49-59

#### **Michel Tremblay**

1. Haftchenary S, Jouk AO, Aubry I, Lewis AM, Landry M, Ball DP, Shouksmith AE, Collins CV, **Tremblay ML**, Gunning PT. Identification of Bidentate Salicylic Acid Inhibitors of PTP1B. *ACS Med Chem Lett.* 2015 Jul 22;6(9):982-6. doi: 10.1021/acsmchemlett.5b00171. eCollection 2015 Sep 10.6.
2. Bunin A, Sisrak V, Ghosh HS, Grajkowska LT, Hou ZE, Miron M, Yang C, Ceribelli M, Uetani N, Chaperot L, Plumas J, Hendriks W, **Tremblay ML**, Häcker H, Staudt LM, Green PH, Bhagat G, Reizis B. Protein Tyrosine Phosphatase PTPRS Is an Inhibitory Receptor on Human and Murine Plasmacytoid Dendritic Cells. *Immunity.* 2015 Aug 18;43(2):277-88. doi: 10.1016/j.immuni.2015.07.009. Epub 2015 Jul 28.
3. Doody KM, Stanford SM, Sacchetti C, Svensson MN, Coles CH, Mitakidis N, Kiosses WB, Bartok B, Fos C, Cory E, Sah RL, Liu-Bryan R, Boyle DL, Arnett HA, Mustelin T, Corr M, Esko JD, **Tremblay ML**, Firestein GS, Aricescu AR, Bottini N. Targeting phosphatase-dependent proteoglycan switch for rheumatoid arthritis therapy. *Sci Transl Med.* 2015 May 20;7(288):288ra76. doi: 10.1126/scitranslmed.aaa4616.
4. Herren DJ, Norman JB, Anderson R, **Tremblay ML**, Huby AC, Belin de Chantemèle EJ. Deletion of Protein Tyrosine Phosphatase 1B (PTP1B) Enhances Endothelial Cyclooxygenase 2 Expression and Protects Mice from Type 1 Diabetes-Induced Endothelial Dysfunction. *PLoS One.* 2015 May 14;10(5):e0126866. doi: 10.1371/journal.pone.0126866. eCollection 2015. Erratum in: *PLoS One.* 2015;10(6):e0130781. Herre, David J [corrected to Herren, David J].

5. Hatzihristidis T, Desai N, Hutchins AP, Meng TC, **Tremblay ML**, Miranda-Saavedra D. A Drosophila-centric view of protein tyrosine phosphatases. *FEBS Lett.* 2015 Apr 13;589(9):951-66. doi: 10.1016/j.febslet.2015.03.005. Epub 2015 Mar 13. Review.
6. Lee D, Kraus A, Prins D, Groenendyk J, Aubry I, Liu WX, Li HD, Julien O, Touret N, Sykes BD, **Tremblay ML**, Michalak M. UBC9-dependent association between calnexin and protein tyrosine phosphatase 1B (PTP1B) at the endoplasmic reticulum. *J Biol Chem.* 2015 Feb 27;290(9):5725-38. doi: 10.1074/jbc.M114.635474. Epub 2015 Jan 13.
7. El-Assaad W, El-Kouhen K, Mohammad AH, Yang J, Morita M, Gamache I, Mamer O, Avizonis D, Hermance N, Kersten S, **Tremblay ML**, Kelliher MA, Teodoro JG. Deletion of the gene encoding G0/G 1 switch protein 2 (G0s2) alleviates high-fat-diet-induced weight gain and insulin resistance, and promotes browning of white adipose tissue in mice. *Diabetologia.* 2015 Jan;58(1):149-57. doi: 10.1007/s00125-014-3429-z. Epub 2014 Nov 9.

### **Josie Ursini-Siegel**

1. Jones LM, Broz ML, Ranger JJ, Ozcelik J, Ahn R, Zuo D, **Ursini-Siegel J**, Hallett M, Krummel D and Muller WJ. 2015. Stat3 establishes an immunosuppressive microenvironment during the early stages of breast carcinogenesis to promote tumor growth and metastasis. *Cancer Research*, pii:canres.2770.2015.
2. **Ursini-Siegel J** and Siegel PM. 2015. The influence of the pre-metastatic niche on breast cancer metastasis. *Cancer Letters*, pii: S0304-3835(15)00683-7.
3. Quigley D, Silwal-Pandit L, Dannenfelser R, Langerod A, Vollan HK, Vaske C, **Ursini-Siegel J**, Troyanskaya O, Chin SF, Caldas C, Balmain A, Borresen-Dale AL and Kristensen V. 2015. Lymphocyte invasion in IC10/basal-like breast tumours is associated with wild-type p53. *Molecular Cancer Research*, pii: molcanres.0387.2014
4. Bolt AM, Sabourin V, Molina MF, Police AM, Negro Silva LF, Plourde D, Lemaire M, **Ursini-Siegel J** and Mann KK. 2015. Tungsten targets the tumour microenvironment to enhance breast cancer metastasis. *Toxicological Sciences*, 143: 165-177.

### **Tsafir Vanounou**

1. Piedimonte S, Wang Y, Bergman S, **Vanounou T**. Early experience with robotic pancreatic surgery in a Canadian institution. *Can J Surg.* 2015 Dec;58(6):394-401.
2. Trabulsi N, Pelletier JS, Abraham C, **Vanounou T**. Preoperative Diagnostic Angiogram and Endovascular Aortic Stent Placement for Appleby Resection Candidates: A Novel Surgical Technique in the Management of Locally Advanced Pancreatic Cancer. *HPB Surg.* 2015;2015:523273. doi: 10.1155/2015/523273. Epub 2015 Sep 28.

### **Antonio Vigano**

1. Huisman HG, Audisio RA, Ugolini G, Montronio I, **Vigano A**, Spiotis J, Stabilini C, de Liguori Carino, Farinella E, Stanojevic G, et al. Screening for predictors of adverse outcome in onco-geriatric surgical patients: A multicenter prospective cohort study. *European Journal of Surgical Oncology*, (2015). Doi.org/10.1016/j.ejso.2015.02.018
2. **Vigano A**, and Morais JA. The elderly patient with cancer: A holistic view. *Nutrition* (2015). Doi.org/10.1016/j.nut.2015.01.001
3. Kilgour RD, Cardiff K\*, Rosenthal L, Lucar E\*, Trutschnigg B, **Vigano A**. Use of prediction equations to determine the accuracy of whole body fat, fat free mass, and



appendicular skeletal muscle mass measurements from a single abdominal image using computed tomography i0068

4. Fuoco D\*, Kilgour RD, **Vigano A**. A hypothesis for a possible synergy between ghrelin and exercise in patients with cachexia: Biochemical and physiological bases. *Medical Hypotheses* (2015). Doi.org/10.1016/j.mehy.2015.09.008
5. Fuoco D\*, di Tomasso\*\* J, Boulos C\*\*\*, Kilgour RD, Morais JA, Borod M, **Vigano A**. Identifying nutritional, functional, and quality of life correlates with male hypogonadism in advanced cancer patients. *ecancer* 2015, 9:561. Doi.org/10.3332/ecancer.2015.561
6. Del Fabbro E, Jatoi A, Davis M, Fearon K, di Tomasso J\*, **Vigano A**. Health professionals' attitudes toward the detection and management of cancer-related anorexia-cachexia syndrome, and a proposal for standardized assessment. *JCommunity Support Oncol* (2015) 13:181-7. Doi.org/10.12788/jcso.01

### **Té Vuong**

1. Kleiman A, Al-Khamis A, Farsi A, Kezouh A, **Vuong T**, Gordon, PH, Vasilevsky C-A, Morin N, Faria J, Ghitulescu G, Boutros M. Normalization of CEA levels post-neoadjuvant therapy is a strong predictor of pathologic complete response in rectal cancer. *Journal of Gastrointestinal Surgery: Volume 19, issue 6* (2015). Page 1106-1112.
2. **Vuong T**, Devic S. High-dose-rate pre-operative endorectal brachytherapy for patients with rectal cancer. *Journal of Contemporary Brachytherapy* 7(2): 183-188. April 2015. PMID: 26034500
3. Breugom AJ, Vermeer TA, van den Broek CBM, **Vuong T**, Bastiaannet E, Azoulay L, Dekkers OM, Niazi T, van den Berg HA, Rutten HJT, van de Velde CJH. Effect of preoperative treatment strategies on the outcome of patients with clinical T3, non-metastasized rectal cancer: a comparison between Dutch and Canadian expert centers. *European Journal of Surgical Oncology* 41(8): 1039-1044. May 2015. pii: S0748-7983(15)00433-3
4. Néron S, Perez S, Benc R, Bellman A, Rosberger Z, **Vuong T**. The Meaning and Experience of Patients Undergoing Rectal High-Dose Rate Brachytherapy. *Cancer Nursing* 39(1), 2015. Epub Ahead of Print. doi: 10.1097/NCC.0000000000000246
5. Perez S, Neron S, Benc R, Rosberger Z, **Vuong T**. Patients' Experience of Rectal High Dose Rate Brachytherapy. *Cancer Nursing: An International Journal for Cancer Care* 03/2015; Publish Ahead of Print(1). DOI: 10.1097/NCC.

### **Michael Witcher**

1. Marques M, Beauchamp MC, Laskov I, Qiang S, Gotlieb WH and **Witcher M\*** Chemotherapy depletes PARP1 protein in ovarian cancer tumors: Implications for future clinical trials involving PARP inhibitors. *BMC Medicine*. 2015 Sep 9;13(1):217.
2. Peña-Hernández R, Marques M, Hilmi K, Zhao T, Saad A, Alaoui-Jamali MA, Del Rincon SV, Ashworth T, Roy AL, Emerson BM, **Witcher M\*** Genome-wide targeting of the epigenetic regulatory protein CTCF to gene promoters by the transcription factor TFII-I. *Proc Natl Acad Sci U S A*. 2015 Feb 17;112(7):E677-86.
3. Anti-cancer properties of *Phyllanthus emblica* (Indian Gooseberry) Zhao T, Sun Q, Marques M and **Witcher M\*** *Oxidative Medicine and Cellular Longevity*. 2015; 950890. doi: 10.1155/2015/950890.

4. Marques M, Hernandez R and **Witcher M\*** Genome wide analysis of the role of the general transcription factor TFII-I in regulating gene expression and targeting CTCF binding to gene promoters. *Genomics Data*, Volume 4, June 2015, Pages 17–21

**Jian Hui Wu**

1. Hsieh J, Ng S, Bosinger S, Wu JH, Tharp GK, Garcia A, Hossain MS, Yuan S, Waller EK, Galipeau J. A GMCSF and IL7 fusion cytokine leads to functional thymic-dependent T-cell regeneration in age-associated immune deficiency. *Clin Transl Immunology*. 2015 May 8;4(5):e37. doi: 10.1038/cti.2015.8. eCollection 2015 May.